

Driving Innovation, Advancing Patient-Centered Care

2023 ANNUAL REPORT



Kellogg Cancer Center

NorthShore is now Endeavor Health, reflecting the exciting future of our nine-hospital system and the continued growth and integration of excellent care.

Though our name may be changed, at the Endeavor Health Cancer Institute Kellogg Cancer Centers, we continue to push boundaries, offering pioneering treatment, delivering compassionate care and pursuing meaningful innovation—all in service of patients and families right here in our communities.

Providing the most advanced, personalized care to individual patients is at the core of everything we do. Our team of collaborative specialists harness state-of-the-art technology and vast experience to offer the latest therapies to improve outcomes for patients.

Simultaneously we're growing our pioneering research efforts, driving new knowledge and evidence-based clinical practices that not only help patients today, but pave the way for even better outcomes tomorrow.

Endeavor Health is playing an exciting role in a growing number of national research initiatives, building on our leadership in molecular diagnostics, genomics and more, as you'll see in this report.

Our fellowship-trained subspecialists, multidisciplinary tumor boards, high surgical and medical oncology patient volumes, and extensive access to clinical trials ensure that our patients receive truly world-class care without having to leave their own communities.

Our academic clinicians believe in working together and value the opportunity to teach the next generation of physician leaders in our growing residency and fellowship programs. As a respected academic medical program, our clinicians and support staff remain focused on our community-connected care. New recruits from the most prestigious fellowship programs across the country choose to practice here because of the collaborative culture and the commitment to academics and excellence in patient care.

We remain incredibly grateful to the many patients and families who support our cancer program and the Kellogg Cancer Centers with philanthropic donations. Charitable donors are vital to our efforts to improve care through cutting-edge research, and donations are also essential to our many patient support programs. We thank each and every donor whose support makes a meaningful difference in the lives of countless patients.

While we offer comprehensive care for the full range of cancers, including the most complex and rare cases, this report highlights just a few areas of exciting new innovation. We thank you for your interest in our mission of patient-centered, community-focused excellence.



Bruce Brockstein, MD
Medical Director,
NorthShore Kellogg Cancer Center
Division Head, Hematology/Oncology
Kellogg-Scanlon Chair of Oncology

Seth Krantz, MD
Division Head, Thoracic Surgery
Chairman, NorthShore Cancer Committee

Collaborative Surgical Interventions for Complex Cases

Endoscopic endonasal skull base surgery uses tiny cameras to navigate the nasal sinuses in order to access the base of the skull and remove tumors and malignancies deep in the brain. This unique approach allows for the minimally invasive treatment of complex tumors through a natural opening—the nose—that would otherwise require large incisions and prolonged recoveries.

Over the last decade, the fellowship-trained team of neurosurgeon Ricky Wong, MD, and otolaryngologist Joseph Raviv, MD, have developed a uniquely collaborative and successful skull base program that allows them to tackle even the most complex cases.

“It takes each of our skill sets working together to accomplish these surgeries,” said Dr. Raviv. Each case begins with an incredible amount of planning and advanced imaging that enables the surgeons to meticulously detail the steps of the procedure from getting to and removing tumors to reconstructing the skull base.

Using their different perspectives to achieve a common goal over the course of hundreds of cases has resulted in tremendous patient outcomes. This synergy creates efficiency that translates into shorter procedure times, fewer complications and faster recovery. Many of our patients go home within a day of their surgery.

Beyond technical expertise, Drs. Wong and Raviv share a common philosophy and approach to patient care. “We really connect with all our patients,” said Dr. Wong. “When I need to make decisions intraoperatively, I always think what would I want if this were me. Every fraction of a millimeter makes a difference in the periphery of these tumors in terms of brain function, nerves and the chance a cancer can come back.” This philosophy has kept the skull base team at the forefront of innovation and has drawn neurosurgeons and otolaryngologists from across the country to NorthShore’s Grainger Center for Simulation and Innovation to be trained in these techniques.

KELLOGG CANCER CENTER BY THE NUMBERS

107	CLINICAL TRIALS
91	PUBLICATIONS
4,452	NEW CASES
30	ONCOLOGISTS
27	ONCOLOGY SERVICE LOCATIONS
167	ONCOLOGY PRACTITIONERS AND CLINICIANS



Drs. Ricky Wong (left) and Joseph Raviv

Cancer-free New Mom Grateful for Advanced Care

Jennifer Kehoe was midway through her first pregnancy in late summer 2020 when she started feeling very congested. A couple months later, she began experiencing severe nose bleeds and eventually was unable to breathe through her right nostril.

She made an appointment with expert otolaryngologist and skull base surgeon Joseph Raviv, MD, but still was not overly alarmed.

“He knew from the moment he looked at me that it was serious,” said Kehoe. “I tend to be a nervous person around medical things and I feel so fortunate I ended up with him. I developed a trust with him that first day.”

Kehoe’s trust was well-placed as Dr. Raviv and neurosurgeon Ricky Wong, MD, have built an exceptional, collaborative program for endoscopic skull base surgery to remove malignancies in the sinuses, nasal cavities and parts of the brain near the sinuses.

Dr. Raviv performed multiple biopsies on the mass in Kehoe’s nose. The results were terrifying as she soon learned she had an aggressive cancer. “Everything after that happened very quickly,” she recalled. Dr. Raviv and Dr. Wong presented the complex case to the Kellogg Cancer Center tumor board and consulted with NorthShore’s Maternal-Fetal Medicine team for high-risk pregnancies. Comprehensive, multidisciplinary planning led to the right approach for Kehoe and her baby.

Together, the team decided she should deliver the baby first and then have surgery to remove the tumor. At 35 weeks, Kehoe gave birth to a healthy 7-pound, 9-ounce baby at NorthShore Evanston Hospital. Three days later, she was transferred to the operating room to have the tumor removed on her 37th birthday.



Jennifer (left), Teddy (center) and Ryan Kehoe

The surgery was even more complex than anticipated, but the tumor was fully removed through her nose. “I am forever grateful for the amount of work they did and that they were able to go through my nose,” said Kehoe.

Pathology revealed that the margins around the tumor were clean, which was a huge relief as Kehoe focused on healing before beginning radiation and chemotherapy under the guidance of medical oncologist Bruce Brockstein, MD and radiation oncologist Vathsala Raghavan, MD.

“Dr. Brockstein, Dr. Raghavan, Dr. Wong and Dr. Raviv worked seamlessly as a team for me, and they all had my trust,” recalled Kehoe. “I truly believed they knew what to do for me.”

Kehoe is now close to three years of being cancer-free following her surgery, and her son Teddy is a very smart and funny toddler who loves preschool and dogs.

“Every time I see her, she brings me a new photo of her son,” said Dr. Raviv. “This is why we do what we do. Cases and patients like this are the reason we practice.”

“Her story really highlights what we’re able to do, approaching each patient as a person, not just a disease process,” said Dr. Wong. “I believe our patients see us as more than just their surgeons, and we definitely see them as more than cases.”

“I feel very fortunate to have the team I did,” said Kehoe. “Dr. Raviv, Dr. Wong, Dr. Raghavan and Dr. Brockstein are all very highly skilled and gifted doctors—but even more so, they’re extraordinary people. They made me feel like family throughout this whole experience and not just like my doctors. I will be forever grateful for all of them.”

Revolutionary Care for Rectal Cancer Patients



Lina Hoffman, NP (left) and Dr. Monika Krezalek

Exciting advances in the treatment of both early and advanced rectal cancer are offering patients dramatic improvements in quality of life. Kellogg Cancer Center's Rectal Cancer Program Director Monika Krezalek, MD, is leading multidisciplinary efforts incorporating the latest evidence-based new treatment and surveillance protocols for rectal cancer patients.

Dr. Krezalek is pioneering the latest approach in robotic, minimally invasive surgery for early rectal cancers. The traditional low anterior resection approach for these cancers is major surgery that often results in a temporary or permanent ostomy for patients. Up to 60% of patients undergoing the major surgery have lasting symptoms that negatively affect their quality of life, including significant changes in bowel habits such as difficulty emptying, urgency, frequency and soiling, explained Dr. Krezalek. This substantial operation also carries the risk of pelvic nerve injury that can result in urinary and sexual dysfunction.

Offering patients with early rectal cancers the new and less invasive approach of robotic transanal minimally invasive surgery (R-TAMIS) has been revolutionary. Dr. Krezalek published her study on the approach in *Diseases of the Colon & Rectum* and has been a leader in the promising trend of organ preservation in early rectal cancer.

Treatment trends for locally advanced rectal cancers include total neoadjuvant chemoradiotherapy (TNT) and "watch and wait" protocols when a complete clinical response to TNT is followed by close surveillance rather than the traditional course of major pelvic surgery. In many instances, this translates to avoiding a permanent colostomy in patients with low rectal cancers. Additionally, clinical trials have demonstrated TNT protocols are superior to conventional approaches of chemoradiation and adjuvant chemotherapy in terms of higher rates of complete clinical response, less toxicity and longer rates of survival.

"Most patients are devastated by the news of having cancer," said Dr. Krezalek. "These new treatment protocols offer them more options and hope for better quality of life once treatment is complete." Dr. Krezalek acknowledged that surgery remains an important treatment modality for many patients with advanced rectal cancers.

All rectal and colon cancer patients are presented at regular tumor board sessions involving surgeons, medical oncologists, radiologists, pathologists and radiation oncologists, and cases are thoroughly reviewed by the collaborative team to determine the best individual approaches to care.

Kellogg Cancer Center's Rectal Cancer Program Key Team Members



William Bloomer, MD



Carolina Soto Chervin, MD



Monika Krezalek, MD



Robert Marsh, MD



Joseph Muldoon, MD



Ranjeev Nanda, MD



Ariel Polish, MD



James Spitz, MD



K.T. Weber, MD

Prestigious NAPRC Accreditation on the Way

Kellogg Cancer Center is in the process of joining an elite group of organizations recognized by The American College of Surgeons National Accreditation Program for Rectal Cancer (NAPRC) this year. Spearheaded by Dr. Krezalek, the accreditation process reflects the program's commitment to the latest evidence-based gold standard treatments and multidisciplinary care.

Currently, there are just 82 NAPRC-accredited programs in the United States, with only seven in Illinois. "NAPRC accreditation efforts reflect the commitment of our multidisciplinary team to provide evidence-based quality care to our rectal cancer patients," said Dr. Krezalek.

Surgical Expertise Preserves Quality of Life

When her internist suggested a screening colonoscopy for Mary (who asked that her real name not be used), the 49-year-old thought, “Better safe than sorry.” She’s now thinking, “If I had waited, who knows what would have happened?”

Two days after her first colonoscopy, Mary received a call that one of the rectal polyps removed during her colonoscopy showed she had cancer. She was referred to colon and rectal surgeon Monika Krezalek, MD, and further diagnostics including an MRI, CAT scan and blood work confirmed that the cancer was very early. “I was shocked, but hopeful,” said Mary. “It was fortuitous to find it early.”

Meeting Dr. Krezalek was also a positive. “She was very helpful and walked my husband and me through all the options,” said Mary. “She even encouraged us to get a second opinion.” After meeting with another physician at a regional academic medical center, Mary was confident that Dr. Krezalek was the right choice.

An expert in transanal minimally invasive surgery, Dr. Krezalek was hopeful that Mary’s cancer could be removed with robotic transanal minimally invasive surgery (TAMIS), avoiding major surgery and the associated risks and changes to quality of life. She explained that she wouldn’t know for sure whether Mary would be

able to avoid major surgery until the mass was removed and assessed by a pathologist under the microscope. Dr. Krezalek was able to successfully perform the robotic TAMIS excision in an outpatient procedure, and Mary was home a few hours later. On review by the pathologist, the cancer was in fact very early, confirming that surveillance could be undertaken instead of the major rectal resection.

“I had the surgery on a Thursday and was back to work by Monday. I never even took the pain medicine that was prescribed,” said Mary, who now undergoes cancer surveillance every three months with blood work and rotating MRIs, CAT scans and ultrasounds as well as exams with Dr. Krezalek.

“I feel strong and optimistic about my future,” said Mary, who enjoys spending time with her family and two grandchildren.



“I am so grateful Dr. Krezalek is my doctor,” said Mary. “She’s super knowledgeable, caring and honest, and I feel really fortunate to be her patient. You can tell that she really cares about you and your health.”

“It’s very gratifying to take care of patients like Mary and offer these minimally invasive procedures that treat the cancer and help preserve their quality of life,” said Dr. Krezalek.



Dr. Monika Krezalek

Below: Microscopy of colon cancer cells, magnification x400




Increasing Immunotherapy Treatment Innovations

Kellogg Cancer Center first introduced checkpoint inhibitor immunotherapy when medications became available through clinical trials, and we remain ahead of the curve in offering immunotherapy as a pioneering form of treatment for many types of cancers.

The recent introduction of CAR T-cell therapy has been transformative for lymphoma patients. One of the first non-university-based, certified CAR T-cell treatment programs in the state, the Kellogg Cancer Center initiative is led by hematologist David Grinblatt, MD. The pioneering, FDA-approved therapy is the best new option for patients with relapsed or refractory lymphoma, offering game-changing benefits for those whose disease was not responsive to other treatments.

In-house expertise in managing CAR T-cell patients will help pave the way for offering other innovative treatments. FDA-approved cellular therapies are available for many blood cancers and are on the horizon for many solid tumor malignancies. Today, more than one-third of Kellogg Cancer Center patients are treated with immunotherapy medications.

Our immunotherapy program involves a comprehensive, collaborative team of specialists across a range of disciplines with experience in helping manage side effects and optimizing overall wellness.



Top: Drs. Andrew Freeman (left) and Mehraboon S. Irani
Bottom: Drs. David Grinblatt (left), Lynne Kaminer (center) and Amy Wang

First CAR T-Cell Patient Thriving

M

ick Jackson first battled lymphoma six years ago with surgery and chemotherapy under the expert guidance of

NorthShore hematologist Lynne Kaminer, MD. “I had a lot of faith in her and was very confident I would be cured,” said Jackson, who was indeed in remission until he faced an atypical late relapse last September.

It’s more common for high-grade lymphoma to come back in the first two to three years,” explained Dr. Kaminer. “In Jackson’s case, his relapse was extensive with cancer in his bone marrow, liver and lymph nodes.”

After undergoing chemotherapy, it was clear the 74-year-old retired computer programmer was not a good candidate for a stem cell transplant. However, CAR T-cell treatment—pioneering, FDA-approved therapy and the new gold standard for patients like Jackson—proved to be a very promising option.

Dr. Kaminer explained that Jackson would be NorthShore’s first CAR T-cell patient in the new program led by hematologist David Grinblatt, MD. Then she walked him and his wife through the protocol, including potential side effects.

“I gave her the go-ahead the next day,” said Jackson. “I had total trust in her.”

CAR T-cell therapy involves chimeric antigen receptor (CAR) genetically modified T cells (a type of immune cells) that are designed to recognize and activate specific tumor cell molecules to destroy malignant cells. Patients’ own immune cells are collected in a process similar to dialysis, engineered to fight the cancer cells, and are then given back to the patient, harnessing the body’s own immune system to attack cancer.

Jackson spent 11 days in Evanston Hospital when he received the CAR T



infusions and was closely monitored by a multidisciplinary team of specialists well versed in the major side effects of the treatment.

“All of the nurses at Kellogg were wonderful,” he said. “As a rule, I really don’t like medicine and hospitals, but this all worked out so well for me.”

After several weeks of feeling very tired, Jackson began to regain his strength. Soon he was back to his active lifestyle including regular exercise, cycling, philosophy classes, reading and writing.

“It’s very gratifying to care for patients and know that we can offer these innovative therapies,” said Dr. Kaminer, who is hopeful about future applications for CAR T and growing numbers of bispecific therapies for lymphoma and other cancers.

A negative PET scan six months post-treatment confirmed that Jackson is now cancer-free. “I’m confident I have many years ahead of me,” he said.

Expanded Treatment Options for Bladder Cancer

Innovative treatment options for advanced and metastatic bladder cancer patients are offering new hope for people for whom other therapies have failed. New immunotherapy drugs, neoadjuvant chemotherapy and post-cystectomy options are among the advanced treatment offerings at Kellogg Cancer Center's growing program for urologic cancer.

"We are seeing up to 70% response rates with the latest immunotherapy drugs for advanced bladder cancer patients," said lead urologic oncologist Kristian Novakovic, MD. In the last two years, the options for treatment of this often devastating disease have dramatically expanded, as has our program. Urologic oncologist Craig Labbate, MD, who did his residency at the University of Chicago and fellowship at MD Anderson Cancer Center, joined the team last year.

Kellogg Cancer Center patients have access to the latest medications through clinical trials; the most advanced robotic, computer-assisted and minimally invasive surgical techniques; and tri-modal therapy with chemo, radiation and surgery.

Fellowship-trained surgeons and oncologists work collaboratively with multidisciplinary specialists to assess



Dr. Kristian Novakovic

individual patients and, where appropriate, offer more conservative approaches to treatment. While bladder removal remains the gold standard treatment for invasive cancers, it can be a quality of life altering event, said Dr. Novakovic. Our ability to perform robot-assisted, nerve-sparing surgery and advanced bladder substitutions can help protect sexual and urinary function.

We continue to expand our program for managing all urologic malignancies, especially bladder cancer. Dedicated nurse navigators for genitourinary cancer patients are helping streamline the patient experience and create

more seamless communication with all related specialists. An Enhanced Recovery After Surgery (ERAS) protocol for bladder cancer is in the works joining our existing protocol for prostate cancer. Specially trained nurses help with all facets of patient education, particularly preparing for surgery and, when necessary, adapting to life with a urinary tract stoma. Patients also have access to sexual health nurse practitioners to aid in their recovery of sexual function following surgery. Our goal is to leverage the strengths of NorthShore as a community health system, providing the most advanced care available.

Cardio-oncology Center of Excellence

Joining just 26 other hospital systems in the country and earning gold status recognition from the International Cardio-Oncology Society (IC-OS), NorthShore was awarded the prestigious IC-OS Center of Excellence Designation.

Led by Jason Robin, MD, our cardio-oncology program has grown dramatically since its inception in 2019 and was recognized by IC-OS for its "exceptionally high concentration of expertise and related resources" to provide the best patient outcomes.

Dr. Robin and the cardio-oncology team have published more than 20 peer-reviewed manuscripts; are collaborating with Massachusetts General Hospital in the pioneering ATRIUM clinical trial related to evaluating and managing myocarditis in patients receiving immunotherapy; and have developed numerous quality improvement projects that impressed the IC-OS review committee.

Rupa Patil, MD, Tariq Azam, MD, and Amit Pursnani, MD, join Dr. Robin as key members of the cardio-oncology

clinical team, providing highly specialized heart care for patients with cancer. The potential risk of cardio-toxicity from cancer treatment puts cancer patients at an increased risk of developing certain cardiovascular conditions. Prevention and early intervention are key to limiting cardiac complications that can interfere with essential cancer treatments.

"This honor recognizes a true team effort and reflects the fact that our patients can trust that they are receiving the most advanced cardiovascular care," said Dr. Robin.

Developing New Therapies for Advanced Endometrial Cancers

NorthShore was involved in one of two major randomized Phase III, placebo-controlled trials that have shown that adding immunotherapy to standard chemotherapy significantly increases benefits for patients with advanced and recurrent endometrial cancer.

“It’s exciting to finally have this new standard of care for advanced and recurrent endometrial cancers,” said gynecologic oncology specialist Tilley Jenkins Vogel, MD. “Having these drugs available in the frontline setting will be a game-changer for patients.” Kellogg Cancer Center patients involved in the trial are still on the protocol, and the results have been phenomenal, added Dr. Jenkins Vogel.

Both studies were published in *The New England Journal of Medicine* in March 2023 and each demonstrated “significantly longer progression-free survival” with the addition of an immunotherapy drug to chemotherapy treatment.

Many other trials are in the pipeline, promising other new therapeutic options. “It’s an exciting time in the field, and everything is moving so fast,” said Dr. Jenkins Vogel. “There are a lot of maintenance therapies on the horizon, and there may be some patients who won’t need chemotherapy.”

For example, a large, international Phase III trial is currently underway looking at the use of combination therapy with a checkpoint inhibitor (pembrolizumab) plus a multikinase inhibitor (lenvatinib) as first systemic treatment in patients with advanced and recurrent endometrial cancers—cohorts who have historically been treated with traditional chemotherapy as the standard of care.

While there are certain endometrial cancer subgroups that will predictably respond to immunotherapy based on their specific molecular subtype/profile, the most common endometrial cancer subtype responds much less robustly to checkpoint inhibitor therapy. For that group, which accounts for a majority of endometrial cancer patients, effective front- and later-line treatment and maintenance options are currently lacking. Dr. Jenkins Vogel is serving as the institutional principal investigator for yet another major multi-site post-chemotherapy maintenance trial with a novel oral agent for advanced and recurrent endometrial cancer patients who do not have a biomarker for response to immunotherapy.

Progress in molecular profiling is helping drive new therapies for patients with endometrial and other gynecologic cancers who have previously had limited options.

Dr. Jenkins Vogel was a co-author on another clinical trial presented this year that demonstrated positive results using targeted combination therapy for a rare subgroup of ovarian cancer patients. Enrollment of NorthShore patients in this pivotal study contributed to these practice-changing results.

A robust clinical trial portfolio is just one element of Kellogg Cancer Center’s strong gynecologic oncology program, long recognized for leadership in clinical care and promising research related to ovarian and endometrial cancers.



Dr. Tilley Jenkins Vogel

Advocating for Early Detection of Lung Cancer

A lung cancer screening event held at Highland Park Hospital in September was part of Kellogg Cancer Center's ongoing mission to raise awareness of and access to vital, lifesaving screening for those at higher risk of developing lung cancer.

Feedback from participants was incredibly positive, and 21 people were scheduled for low-dose CT scans following the event. At least one person was sent on for further diagnostics after the scan.

The use of CT scans for people at high risk for developing lung cancer has been linked to a dramatic 20% reduction in lung cancer deaths. The screening is now covered by Medicare and insurance for patients who meet the risk criteria, yet too few of those eligible for screening are actually having the scans.

Individuals who currently smoke, or who have quit within the last 15 years and who are 50 to 80 years old are encouraged to consider the screening. Current guidelines suggest annual screening for people with a 20 pack-year history of smoking—a pack year equals smoking one pack per day for a year, smoking two packs a day counts as two pack years and so on.

NorthShore was an active participant in the International Early Lung Cancer Action Program (I-ELCAP) and has been a longtime advocate for increased screening for those at elevated risk.

"We are working to underscore the importance of screening as a way to catch cancer sooner when it's far more treatable," said Seth Krantz, MD, Head of Thoracic Surgery and chairman of the NorthShore Cancer Committee. "The scan rates for eligible patients, those at higher risk of developing lung cancers, are still very low locally and nationally."



Breast Cancer Program Recognized for Excellence

Our breast health program was recognized for a high level of achievement and providing excellent care by the National Accreditation Program for Breast Centers (NAPBC), a quality program of the American College of Surgeons (ACS). Citing a rich history and an array of strengths, NAPBC granted the program reaccreditation.

Nursing competency, genetics and an emphasis on personalized medicine and patient education were some of the strengths highlighted in the accreditation survey.

Katharine Yao, MD, Director of Breast Cancer Research, chairs the national ACS NAPBC leadership committee, and Catherine Pesce, MD, is our NAPBC Breast Surgical Program Director.

National Recognition for Oncology Program

NorthShore – Edward-Elmhurst Health was named to *Becker's Hospital Review's* 2023 list of "100 hospitals and health systems with great oncology programs." "The system's multidisciplinary, subspecialty care model and collaborative team approach to patient care" was noted in the listing, as was our partnership with the University of Chicago Pritzker School of Medicine and academic and research activities.

The *Review* also notes "The Kellogg Cancer Center offers pioneering techniques through Kellogg Cancer Genomic Initiative to help identify, diagnose and treat diseases.

The Center was also an early adopter of immunotherapy to treat advanced cancer."

Innovative Research Driving Clinical Excellence

Cancer Moonshot Founding Member

Accelerating Innovation with CancerX

NorthShore – Edward-Elmhurst Health (NS-EEH) was recognized for a unique ability to innovate and implement, like its pioneering approach with genomics and prevention and screening in primary care. A founding member of the CancerX public-private partnership, NS-EEH is one of only two Illinois entities represented in this pioneering collaboration.

CancerX focuses on commoditizing best practices and aligning incentives; coordinating access to research, mentorship, resources and other collaborative opportunities; and demonstrating success in practice to drive broad adoption—all with an eye toward reducing the incidence and burden of cancer.



Dr. Peter Hulick

“It’s exciting to play a role in this ambitious project to accelerate scientific discovery and care in cancer,” said Peter Hulick, MD, The Janardan D. Khandekar, MD, Chair of Personalized Medicine and Medical Director of Mark R. Neaman Center for Personalized Medicine. “We have a history of being able to implement at the bedside in a very nimble way, and we believe our strengths related to genomics and digital health solutions will help advance the effort.”

The inaugural project for the partnership is “advancing digital innovation to improve equity and reduce financial toxicity in cancer treatment.”

NS-EEH joined other prominent health systems and biotech companies as founding members of President Joe Biden’s Cancer Moonshot initiative working to develop cures for cancer.


President Biden reignited the Cancer Moonshot project with an impressive goal of cutting the U.S. cancer death rate by at least 50% in the next 25 years. To accelerate the development of treatments and cures and boost innovation in the fight against cancer, the Biden administration launched CancerX in March 2023.



Dr. Jianfeng Xu, DrPH, Vice President of Translational Research, has led efforts using genomic data to improve cancer detection, treatment and patient outcomes.

Education Highlights

Breast Cancer Surgical Fellowship



Drs. Callie McAdams (left) and Catherine Pesce

A one-year Breast Surgical Oncology Fellowship Program in partnership with NorthShore and the University of Chicago Medicine continues to draw a growing group of highly qualified candidates, gaining national recognition for clinical, educational and research excellence.

Led by Catherine Pesce, MD, Program Director for the Breast Surgical Oncology Fellowship, the fellowship is in its third year and has successfully matched a fellow for next year's program.

"The success of the program speaks to the high quality of our team of breast surgeons and the large volume of breast cancer cases," said Dr. Pesce. The Kellogg Cancer Center's fellowship-trained surgeons offer expertise and training in the most advanced techniques including nipple-sparing mastectomies and oncoplastic breast surgery. "We are one of the few sites in the country participating in a clinical trial for robotic nipple-sparing mastectomies," added Dr. Pesce.

"This has been a really great experience," said current fellow Callie McAdams, MD. "The system has everything a patient needs to receive great care—great surgeons, oncologists, plastic surgeons, radiation oncologists, emotional psychosocial support, a survivorship program and more."

Dr. McAdams said one of the draws of the fellowship for her was the large and varied patient population ranging from benign simple cases to the most complex. "I feel like I'm getting a very well-rounded surgical training, and the way everybody teaches here has helped inform how I want to shape my own practice," said Dr. McAdams. "If my aunt or mom had breast cancer, I would be glad to have them come here for care. That says a lot about the program."

The most common feedback Dr. Pesce and colleagues hear from fellows is that they'd like to stay on staff, she said, noting that last year's fellow has joined the oncology team at Edwards-Elmhurst Health.

Oncology Resident Elective

Kellogg Cancer Center faculty continue to draw rave reviews from residents who benefit from working with experienced clinicians with a shared commitment to academic excellence. Residents rotate through different oncologic subspecialties in the outpatient clinics, gaining a thorough overview of each type of malignancy, explained Oncology Resident Program Director Britt Hanson, DO.

Residents rotating through the oncology elective are provided reading material regarding specific malignancies and work one-on-one with an oncologic physician seeing patients in the clinical setting. The residents also see oncology patients in the inpatient setting to provide additional educational value. Additionally, residents attend cancer-specific tumor boards to discuss patient cases in a multidisciplinary manner.

"The strength of our program reflects our team's desire to help train the next generation of leaders in medicine," said Dr. Hanson. The goal of the oncology elective is to give the resident a broad, in depth understanding of oncologic knowledge that they can rely on for the rest of their career.



*Oncology Resident Program Director
Dr. Britt Hanson*

Comprehensive Support Services

Thanks in part to our many generous donors, the Kellogg Cancer Center is able to provide patient- and family-centered care. In addition to an ongoing focus on prevention, early detection and advanced treatment options for cancer, we are also committed to offering patients and families a full range of resources to help navigate and manage their cancer journey.

From emotional and spiritual support to special nutritional guidance, integrative medicine services, assistance with practical needs like transportation or financial aid, and a robust survivorship program, the extended Kellogg Cancer Center team delivers comprehensive, compassionate support.

Integrative Oncology Clinic

Kellogg Cancer Center patients now have the opportunity to meet one-on-one with an Integrative Oncology (IO) Nurse Practitioner at the IO clinic at the Evanston Hospital site. The program provides for an initial evaluation with ongoing follow-up visits, and patients can be seen at any time from diagnosis to treatment through survivorship.

IO Nurse Practitioners Sara Reynolds and Maggie Keller each completed a year-long IO Scholars Program funded by the National Cancer Institute at the University of Michigan and have extensive experience working with oncology patients.

Keller and Reynolds work collaboratively with the oncology clinical team and offer evidence-based complementary therapies incorporating natural products, mind and body practices, lifestyle modifications, and nutrition designed to help patients enhance their health and overall wellbeing.

The IO Nurse Practitioners are working with patients with a wide variety of cancer types to help them achieve better sleep, manage stress, improve daily living, and offset or decrease challenging symptoms from cancer treatments.

“The patients are really appreciative that Kellogg provides this service,” said Reynolds. “It’s empowering for patients to focus on themselves, and it’s been gratifying for us to be able to help them prioritize and optimize their overall health while going through their cancer journey,” added Keller.

The IO Nurse Practitioners partner with NorthShore’s robust Integrative Medicine Program and appreciate the many resources that are available for patients.

Enhanced Navigation

Having a consistent presence from the day of diagnosis through various stages of treatment and into survivorship benefits patients in what can be an all-consuming effort. Our specially trained, compassionate nurse navigators provide this important frontline support for patients, and we’re working to further enhance the navigation process. Additional nurse navigators and social workers are coming together collaboratively to refine our efforts to seamlessly guide patients through the entirety of this challenging time.



Nurse Practitioners Sara Reynolds (left) and Maggie Keller

Helping Patients Reduce Hair Loss

Hair loss is one of the most feared and common side effects of chemotherapy, and its emotional impact can add to the trauma of cancer treatment. The Paxman Scalp Cooling System® offers a treatment that can prevent hair loss caused by certain chemotherapy drugs. Scalp cooling has been most effective for patients undergoing certain chemotherapy regimens for early-stage breast cancer.

Kellogg Cancer Center now has a liaison who works directly with patients using the scalp cooling system. A former patient, the Paxman liaison works with our breast cancer collaborative nurses and is able to offer hands-on support. Patients continue to express gratitude for the scalp cooling system and the experience of working with someone who understands what they're going through.

Patient Financial Assistance

Our experienced Patient Financial Advocates are available to help patients navigate insurance coverage and medical bills. They can also help access and determine eligibility for our financial assistance program and philanthropy-funded patient assistance grants.

Specific patient assistance grants are generously funded by donors and are used to help patients in need with medical bills, medications and other related costs. Requests for these grants have continued to rise since the pandemic and continued economic challenges for many individuals and families. Kellogg Cancer Center is committed to removing barriers for essential, lifesaving care.

Vital Philanthropic Support

Since its inception, philanthropy has been a critical aspect of Kellogg Cancer Center's success. The Center was established, in part, by a very generous gift from the Kellogg family more than 40 years ago. Today, donor support is even more essential to helping physicians, nurses and the entire clinical team deliver exceptional, personalized care to every patient. From employing the latest novel treatments and access to cutting-edge clinical trials, to providing a full range of unique support services, none of this could be possible without community investment.

The fast pace of change in treating cancers and new discoveries is a positive reality. More people are beating cancer than ever before thanks to exciting advancements in research and a commitment by physicians to harness the power of the body's own immune system. There are more options delivering better outcomes and brighter futures. Our donors bolster our clinical team members' ability to serve every patient and break down the barriers to care for all—regardless of their ability to pay. Generous philanthropy has helped make Kellogg Cancer Center a trusted community resource when people need it most.

To learn more about how you can support Kellogg Cancer Center, please call Kevin Gray in the NorthShore Foundation at **224-364-7609**. Or visit **foundation.northshore.org**



*Dr. Janardan D. Khandekar, the founding
Head of the Division of Medical Oncology*

Oncology Trials

Breast Cancer

EA1181 Compass (HER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

A011801 The CompassHER2 trials (COMprehensive use of Pathologic response ASSESSment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

S2007 A Phase II Trial of Sacituzumab Govitecan (IMMU-132) for Patients with HER2-Negative Breast Cancer and Brain Metastases

CCTG MA.39: Tailor RT A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

Gastrointestinal Cancer

NRG-GI004/SWOG-S1610 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

UC14-0594 Perioperative FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma

NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

Genitourinary Cancer

Johns Hopkins J1557 Overcoming Drug Resistance in Metastatic Castration-Resistant Prostate Cancer with Novel Combination of TGF- β Receptor Inhibitor LY2157299 and Enzalutamide: A Randomized Multi-Site Phase II Study

NRG-GU008 A Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE)

EA8183 A Phase III Study of Early Intervention After RADICAL Prostatectomy with Androgen Deprivation Therapy with Darolutamide Versus Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

UC13-0540 Afatinib (BIBW 2992) in Advanced Refractory Urothelial Cancer

S1806 Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

CURLu177PSM0001 A Multi-Center, Open-Label, Randomized Phase III Trial Comparing the Safety and Efficacy of ¹⁷⁷Lu-PSMA-I&T Versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Myovant Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)

EA8212-A Randomized Phase III Trial of Intravesical BCG Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

UC20-0736 A Feasibility Study of Education About an Alternative to Chronic LHRH Agonist or Antagonist Therapy in Patients with Prostate Cancer

S2011 Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin Versus No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma

SWOG GAP Trial Genomic Profiling and Clinical Outcomes in Metastatic Castrate-Resistant Prostate Cancer

Gynecologic Cancer

AGCT1531 A Phase III Study of Active Surveillance for Low-Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard-Risk Pediatric and Adult Patients with Germ Cell Tumors

GOG-3026 A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum NRG-GY020: Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NCT# 04214067)

NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCK)

NRG-GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

NRG-GY022 Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin

GOG3073-CORT125124-556 A Phase III Study of Relacorilant in Combination with Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA)

GOG 3066-ZN-c3-005 A Phase II Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-C3 IN Subjects with High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NRG-GY026 A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2-positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

A092104 A Randomized Phase II/III Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

GOG 3065/ZN-c3-004 A Phase II, Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma

For more information about clinical trials, visit
northshore.org/kellogg-cancer-center/clinical-trials

Oncology Trials

Head and Neck Cancers

HCN Tissue bank tissue/body fluid procurement and clinical data collection for patients with malignancies of the head and neck area and/or premalignant changes

NRG HN005 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking-Associated Oropharyngeal Cancer

RTOG 1216 Randomized Phase II/III Trial of Aduvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Merck: MK-7902-009-05 Phase II, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)

Hematology

Connect® MDS/AML The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

CIBMTR Research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries

A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (ages 18-39) with Newly Diagnosed Precursor B-Cell Acute Lymphoblastic Leukemia (ALL)

EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

S1925 Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study

EA9181 A Phase III Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults

S1918 A Phase II/III randomized study of R-miniCHOP with or without CC-486 (oral azacitidine) in patients age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb follicular lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (NCT04799275)

A Pilot Study Assessing Neurocognitive Impairments in Adult Survivors of Adolescent and Young Adult Hematologic Malignancies

A042001 A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Lung Cancer

Lung-MAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer

E4512 A Phase III double-blind trial for surgically resected early-stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein

A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

EA5181 Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

A081801 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO (ACCIO)

S1900E A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer

S2302 Non-Chemotherapy Treatment (Ramucirumab Plus Pembrolizumab) or Usual Care for Advanced Non-Small Cell Lung Cancer Following Immunotherapy

Neuro-Oncology

NRG BN003 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

A071702 A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatic Hypermutated Recurrent Glioblastoma

NCI-Connect Nivolumab Rare CNS Trial 17-C-0102 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers

Brain-Up/U of C A Phase I Study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter-Methylated IDH Wildtype Glioblastoma

Sarcoma

Ayala AL-DES-01 (Ringside) A Phase II/III, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

A092107 A Randomized Phase II Trial with a Safety Lead-In to Evaluate Palbociclib versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma

Skin Cancer

EA6141 Randomized Phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

Other

Carevive OPT-IN® Real-World Treatment Experience of Patients with Breast, Lung, Multiple Myeloma, Acute Myelogenous Leukemia or Ovarian Cancer Using Remote Symptom Monitoring

A151804 Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Genomic Panels Prospective Analysis of the Utility of Routine Incorporation of Genomic Panels into the Care of Patients with Metastatic Cancer

ANTHOS 8 A multicenter, randomized, open-label, blinded endpoint evaluation, phase III study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Anthos 7 A multicenter, randomized, open-label, blinded endpoint evaluation, Phase III study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

continued >

Surgical Oncology Trials

Breast Surgery

EH20-166 The Ergonomic Effects of the Robotic Nipple-Sparing Mastectomy on the Operating Surgeon

EH20-165 Exploring Breast Surgical Oncologists' Attitudes and Comfort Level with Universal Genetic Testing

EH15-297 A randomized Phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy—Alliance A011202

EH20-167 Breast Cancer Stem Cells and Peritumoral Adipose Tissue

EH21-214 The Impact of Breast Cancer Surgical Delays Brought On by the Initial COVID-19 Pandemic Surge on Final Pathologic Tumor Stage

EH17-072 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS

EH17-209 Genetic Determinants of Cooperative Interactions on Breast Cancer Intratumor Heterogeneity

EH18-243 Tell Me Where It Hurts: The Ergonomic Effects of Mastectomies on the Operating Surgeon

EH10-081-ACOSOG Z1071 A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node-Positive Breast Cancer (T0-4, N1-2, M0) at Initial Diagnosis

EH88-077 The Establishment and Maintenance of the NorthShore University HealthSystem Comprehensive Data Registry for Breast Surgeries and Breast Tissue Bank

EH20-301 WhySurg for Men: A Male Breast Cancer Survey for Men with Breast Cancer

EH20-303 The WhySurg Study for Men with Breast Cancer: The Physician Perspective

EH20-171 CROWN Study COVID-19-Related Oncologists' Concerns About Treatment Delays and Physician Wellbeing

EH19-074 A Prospective, Multicenter Investigation of the da Vinci Xi Surgical System in Nipple-Sparing Mastectomy (NSM) Procedures

EH20-348 Retrospective, Multicenter Study of Open Nipple-Sparing Mastectomy (NSM)

EH20-134 The PREPARE Study: Supporting Women with Breast Cancer to Prepare for Treatment

EH20-195 Outcomes of COVID-19 Positive Cancer Patients Compared to Patients without Cancer: A Single Institution Experience

Colorectal Surgery

EH12-468 N1048 A Phase II/III trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision

Head and Neck Surgery

EH17-116 Lipid Tissue from Head and Neck Cancer

Pancreatic Cancer

EH18-265 A Phase III Multicenter, Open-Label, Randomized, Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreato-duodenectomy

EH08-197T Clinical pancreatic cancer database

EH13-433 Comprehensive Assessments for Clinical Care and Surgical Management Among Individuals with Pancreatic Pathology

EH02-186 The Pancreatic Sample Repository

EH17-132 Assessment of Tumor and Treatment Factors as Predictors of Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma Undergoing Pancreaticoduodenectomy, and Efficacy of Pharmacologic Prophylaxis

EH21-215 Extended Post-Operative Thromboprophylaxis After Pancreatic Resection for Pancreatic Cancer Is Associated with Decreased Risk of Venous Thromboembolism in the Minimally Invasive Approach

EH21-099 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Lung and Esophageal Cancer

EH98-136 Establishment and maintenance of a comprehensive thoracic tumor data registry and biorepository

EH18-162 Inherited Cancer Panel Performance in Predicting Outcomes Among Patients Diagnosed with Lung Cancer

EH16-356 Clinical Characteristics of Anti-PD-1/PD-L1 Relapses in Non-Small Cell Lung Cancer (NSCLC)

EH16-079 Retrospective chart review study to look at adequacy of lymph node staging in patients undergoing curative anatomic resection for non-small cell lung cancer

EH16-362 Natural History of Indeterminate Lung Nodules

EH20-111 Non-Small Cell Lung Cancer Tissue Sample Study

Thyroid Surgery

EH14-058 The establishment of a multidisciplinary comprehensive database of patients for thyroid nodular disease

Genitourinary Cancer

EH09-043 A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

EH13-250 Cancer susceptibility: The ICPCG study (International Consortium for Prostate Cancer Genetics)

EH13-446 A retrospective review of patients who have been removed from study EH09-043: A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

EH14-361 SPORE Project 1 Impact of Germline Genetic Variants and Failure of Active Surveillance for Prostate Cancer

EH15-124 Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Through Engagement in Mindfulness Education (REASSURE ME)

EH16-183 Evaluation of the utility of the prostate health index in routine clinical practice

EH22-009 Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate Risk Patient Population

EH08-063 The IMPACT Study: Identification of Men with a Genetic Predisposition to ProstAte Cancer: Targeted Screening in Men at Higher Genetic Risk and Controls

EH23-229 PRostate cancer biomarker detection in Seminal plasMa (PRISM)

EH22-336 Protocol based versus non-protocol based active surveillance for prostate cancer

EH23-148 MRI Screening in Men at High Risk of Developing Prostate Cancer

EH15-091 The Establishment of a Comprehensive Urologic Disease Biorepository and Database

EH23-166 Blue Light Cystoscopy™ with Cysview® (BLC™ with Cysview®) Registry

EH21-338 Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer from Prostate Biopsy

EH16-240 Timing of artificial urinary sphincter placement

For more information about clinical trials, visit
northshore.org/kellogg-cancer-center/clinical-trials



2023 Research Publications

Abdelhamid Ahmed AH, Russell MD, Kyriazidis N, **Silver Karcioğlu A**, Sherman EJ, Ho AL, Fagin JA, Wong RJ, Busaidy NL, Zafereo ME, Sadow P, Park JC, Wirth LJ, Randolph GW. A Phase II study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer. *J Clin Oncol*. 2023 41:16_suppl, TPS6105-TPS6105. Published online May 31, 2023

Abu Hilal M, van Ramshorst TME, Boggi U, Dokmak S, Edwin B, Keck T, ... **Hogg ME**, et al. Collaborators. The Brescia Internationally Validated European Guidelines on Minimally Invasive Pancreatic Surgery (EGUMIPS). *Ann Surg*. 2023 Jul 14. doi: 10.1097/SLA.0000000000006006. Online ahead of print. PMID: 37450702

Al Abbas AI, Hamad AB, Zenati MS, Zureikat AH, Zeh HJ 3rd, **Hogg ME**. Does CT scanning after pancreatoduodenectomy reduce readmission rates: an analysis of 900 resections at a high-volume center. *HPB (Oxford)*. 2022 Jul 1:S1365-182X(22)01512-X. doi: 10.1016/j.hpb.2022.06.012. PMID: 35871133

Bleicher R, Moran M, Rush K, Dietz J, Edge S, Wilke L, Stearns V, Kurtzman S, Klein J, **Yao K**. The Impact of Radiotherapy Delay in Breast Conservation Patients Not Receiving Chemotherapy and The Rationale for Dichotomizing the Radiation Oncology Time Dependent Standard into Two Quality Measures. *Ann Surg Oncol* 2022; 29(1):469-481.

Bouma M, **Wake DT, Moorthy G, Ochs L, Sereika A, Dunnenberger HM, Sabatini L, Mangold MA, Alikhan M, Parilla M, Helseth Jr DL**, Miller N, Yang M, **Khandekar J, Brockstein B, Kaul KL**. Pharmacogenomic Testing and Somatic Next Generation Sequencing of Patients with Advanced Solid Tumors. Poster, *AAMP* 2023.

Ca Shi Z, Wei J, Rifkin AS, Wang CH, Billings LK, Woo JSH, **Talamonti MS, Vogel TJ, Moore E, Brockstein BE, Khandekar JD, Dunnenberger HM, Hulick PJ, Duggan D, Zheng SL, Lee CJ, Helfand BT, Tafur AJ, Xu J**. Cancer-associated thrombosis by cancer sites and inherited factors in a prospective population-based cohort. *Thromb Res*. 2023 Sep;229:69-72. doi: 10.1016/j.thromres.2023.06.023. Epub 2023 Jun 26. PMID: 37419004

Chichura A, Attai DJ, Kuchta K, Nicholson K, Kopkash K, Pesce C, Yao K. Male Breast Cancer Patient and Surgeon Experience: The Male WhySurg Study. *Ann Surg Oncol*. 2022 Oct;29(10):6115-6131. doi: 10.1245/s10434-022-12135-6. Epub 2022 Jul 25. PMID: 35876929; PMCID: PMC9310362

Choi SH, Kuchta K, Rojas A, Mehdi SA, Ramirez Barriga M, Hays S, **Talamonti MS, Hogg ME**. Residents perform better technically, have less stress and workload, and prefer robotic to laparoscopic technique during inanimate simulation. *Surg Endosc*. 2023 Sep;37(9):7230-7237. doi: 10.1007/s00464-023-10216-5. Epub 2023 Jul 3. PMID: 37395804

Choi SH, Kuchta K, Rojas AE, Paterakos P, **Talamonti MS, Hogg ME**. Does minimally invasive surgery have a different impact on recurrence and overall survival in patients with pancreatic head versus body/tail cancer? *J Surg Oncol*. 2023 Jul;128(1):23-32. doi: 10.1002/jso.27240. Epub 2023 Mar 20. PMID: 36938987

D'Angelica MI, Ellis RJ, Liu JB, Brajcich BC, Gönen M, Thompson VM, ... **Talamonti MS**, et al. Piperacillin-Tazobactam Compared with Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial. *JAMA*. 2023 May 9;329(18):1579-1588. doi: 10.1001/jama.2023.5728. PMID: 37078771

Deliere AE, **Kuchta KM, Pesce CE, Kopkash KA, Yao KA**. Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients. *J Am Coll Surg*. 2022 Nov 1;235(5):788-798. doi: 10.1097/XCS.0000000000000326. Epub 2022 Oct 17. PMID: 36102573

Derman BA, Kansagra A, Zonder J, Stefka AT, **Grinblatt DL**, Anderson LD Jr, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasiolec J, Jakubowiak AJ, Enotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase II Measurable Residual Disease-Adapted Study. *JAMA Oncol*. 2022 Sep 1;8(9):1278-1286. doi: 10.1001/jamaoncol.2022.2424. PMID: 35862034

Diebolt JH, Yu KM, Wood S, Ziegler A, France A, Villwock MR, **Alvi SA**, Kakarala K, Shnayder Y, Gan GN, Lominksa CE, Neupane P, Bur AM. Prognostic Implications of Skin Invasion in Locally Advanced Oral Cavity Squamous Cell Carcinoma. *JAMA Otolaryngol Head Neck Surg*. 2022 Aug 2;148(8):1167-1174. doi: 10.1177/0149598221116746. Online ahead of print. PMID: 35917167

Ecanow, Chichura, **Kopkash K, Pesce C, Sullivan M, and Yao K**. Gestational gigantomastia complicated by breast infarctive necrosis in the setting of COVID-19 infection: a case report. *Ann Breast Surg*. 2023; 7:30.

Ehlers SL, Gudenkauf LM, **Kacel EL**, Hanna S, Sinicrope PS, Patten CA, Morrison EL, Snuggerud J, Bevis D, Kirsch JL, Staab JP, Price KA, Wahner-Hendrickson AE, Ruddy KJ. Real-world implementation of best-evidence cancer distress management: Truly Comprehensive Cancer Care. *J Natl Compr Canc Netw*, Volume 21: Issue 6; Online Publication Date: Jun 2023. doi: https://doi.org/10.6004/jnccn.2023.7009

Fefferman M, Kuchta K, Nicholson K, Attai D, Victorson D, **Pesce C, Kopkash K, Poli E, Smith TJ, Yao K**. Patient Values in Breast Cancer Surgical Decision-Making—The WhySurg Study. *Am J Surg* 2023

Fefferman M, Nicholson K, **Kuchta K, Pesce C, Kopkash K, Yao K**. Rates of Bilateral Mastectomy in Patients with Early-Stage Breast Cancer. *JAMA Netw Open*. 2023 Jan 3;6(1):e2251348. doi: 10.1001/jamanetworkopen.2022.51348. PMID: 36652251

Flick ED, Terebello HR, Fish S, Kitali A, Mahajan V, Nifenecker M, ... **Grinblatt DL**. The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research. *Oncologist*. 2023 3;28(8):657-663

Ghosh K, Shakir A, Kuchta K, Seth A, **Sisco M**. Safety and factors affecting same-day discharge following mastectomy and immediate alloplastic reconstruction. *J Surg Oncol*. 2023 Oct 23. doi: 10.1002/jso.27491.

Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, ... **Hogg M**, et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. *Gut*. 2022 May;71(5):961-973. doi: 10.1136/gutjnl-2020-322595. Epub 2021 Apr 13. PMID: 33849943

Hakkaart C, Pearson JF, Marquart L, Dennis J, Wiggins GAR, Barnes DR, ... **Rodriguez GC...Hulick PJ**, et al. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. *Commun Biol*. 2022 Oct 6;5(1):1061. doi: 10.1038/s42003-022-03978-6. PMID: 36203093

Haravu P, Shakir A, Jackson K, Alva D, Feldman J, **Sisco M**, Seth AK. Establishment and Feasibility of an Immediate Lymphatic Reconstruction Program in a Community Health System. *Ann Surg Onc*. In press

Hogg ME. Next-Generation Opioid Scripts-Postpancreatectomy ERAS. *JAMA Surg*. 2023 Sep 6:e234161. doi: 10.1001/jamasurg.2023.4161. Online ahead of print. PMID: 37672262

Hogg ME. The Surgeon, the Center, and the System—Several Styles to Stage Mastery. *JAMA Surg*. 2023 Sep 1;158(9):934. doi: 10.1001/jamasurg.2023.2290. PMID: 37379051

Hogg ME, Melstrom LG. Top Pancreatic Tumor Articles from 2021 to Inform Your Cancer Patients. *Ann Surg Oncol*. 2023 Jun;30(6):3437-3443. doi: 10.1245/s10434-023-13277-x. Epub 2023 Mar 14. PMID: 36917337 Review

Huang A, Kuchta K, Alva D, **Sisco M, Seth AK**. Wise-Pattern Mastectomy with an Inferior Dermal Sling Is a Safe Alternative to Elliptical Mastectomy in Prosthetic Breast Reconstruction. *Plast Reconstr Surg*. In press

Joung RHS, Mullett TW, Kurtzman S, Shafir S, Harris JB, **Yao KA**, Bilimoria KY, Cance WG, Nelson H. Evaluation of a National Quality Improvement Collaborative on Improving Cancer Screening. *JAMA Network Open* 2022; 5(11):e2242354

continued >

Joung RHS, Nelson H, Mullett TW, Kurtzman S, Shafir S, Harris JB, **Yao KA**, Brajcich BC, Bilimoria KY, Cance WG. National Quality Improvement Study Identifying and Addressing Cancer Screening Deficits Due to the COVID-19 Pandemic. *Cancer* 2022; 128 (11): 2119

Karcioglu AS, Dhillion VK, Davies L, Stack BC Jr, Bloom G, Randolph G, Lango MN. Analysis of Unmet Information Needs Among Patients with Thyroid Cancer. *JAMA Otolaryngol Head Neck Surg*. 2023 Feb 1;149(2):110-119. doi: 10.1001/jamaoto.2022.4108. PMID: 36580287

Karcioglu AS, Hartl D, Shonka DC Jr, Slough CM, Stack BC Jr, Tolley N, Abdelhamid Ahmed AH, Randolph GW. Autofluorescence of Parathyroid Glands: A Review of Methods of Parathyroid Gland Identification and Parathyroid Vascular Assessment. *Otolaryngol Clin North Am*. 2023 Aug 25;S0030-6665(23)00131-7. doi: 10.1016/j.otc.2023.07.011. Epub ahead of print. PMID: 37634981

Karcioglu AS, Russell MD, Ahmed AH, Randolph GW. Electrophysiologic RLN and Vagal Monitoring During Thyroid and Parathyroid Surgery Ch 6 in Shrifin AL, Deutsch AD, Randolph GW (eds) *Atlas of Intraoperative Cranial Nerve Monitoring in Thyroid and Head and Neck Surgery*. Switzerland: Springer Nature, July 2023; p 25-40.

Kates M, Chu X, Hahn N, Pietzak E, Smith A, **Shevrin DH**, Crispen P, Williams SB, Daneshmand S, Packiam VT, Porten S, Westerman ME, Wagner LI, Carducci M. Background and Update for ECOG-ACRIN EA812: A Randomized Phase III Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-Naïve High-Grade Non-Muscle-Invasive Bladder Cancer (BRIDGE). *Eur Urol Focus*. 2023 Jul;9(4):561-563. doi: 10.1016/j.euf.2023.06.006. Epub 2023 Jul 6. PMID: 37422371

Katipally RR, Martinez CA, Pugh SA, Bridgewater JA, Primrose JN, Domingo E, Maughan TS, **Talamonti MS**, Posner MC, Weichselbaum RR, Pitroda SP; with the S:CORT Consortium. Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase III New EPOC Randomized Clinical Trial. *JAMA Oncol*. 2023 Sep 1;9(9):1245-1254. doi: 10.1001/jamaoncol.2023.2535. PMID: 37471075 Clinical Trial

Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, **Marsh R**, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM. Efficacy of Preoperative mFOLFIRINOX Versus mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase II Randomized Clinical Trial. *JAMA Oncol*. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319. PMID: 35834226

Kaur A, Kuchta K, Watkin W, Sullivan M, Liu L, Jamshidi P, **Campbell N**, **Brockstein B**, Paintal A. Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma. *Arch Pathol Lab Med*. 2023 Apr 1;147(4):442-450. doi: 10.5858/arpa.2021-0464-OA. PMID: 3586286

Kearns JT, **Helfand BT**. Is Active Surveillance Too Active? *Curr Urol Rep*. 2023 Oct;24(10):463-469. doi: 10.1007/s11934-023-01177-2. Epub 2023 Jul 12. PMID: 37436691

Korrel M, Lof S, Alseidi AA, Asbun HJ, Boggi U, **Hogg ME**, Jang JY, Nakamura M, Besselink MG, Abu Hilal M; International Consortium on Minimally Invasive Pancreatic Surgery (I-MIPS). Framework for Training in Minimally Invasive Pancreatic Surgery: An International Delphi Consensus Study. *J Am Coll Surg*. 2022 Sep 1;235(3):383-390. doi: 10.1097/XCS.000000000000278. Epub 2022 May 20. PMID: 35972156 Review

Krantz SB, **Zeeshan K**, **Kuchta KM**, **Hensing TA**, **Mangold KA**, **Zheng SL**, **Xu J**. Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non-small cell lung cancer. *JTCVS Open*. 2022 Sep 21;12:399-409. doi: 10.1016/j.xjon.2022.09.001. eCollection 2022 Dec. PMID: 36590722

Kroft SH, **Kaul KL**. Regulation of laboratory-developed tests: scoping the issue. *Am J Clin Pathol*. 2023 Sep 1;160(3):222-224. doi: 10.1093/ajcp/aqad060. PMID: 37265228

Lam A, Campbell NP, Russell HM, **Krantz SB**. Complete Pathologic Response of Squamous Cell Carcinoma Abutting an Internal Mammary Bypass Graft. *Ann Thorac Surg Short Reports*. 2023 Jan 3

Lapkus M, Horowitz B, Sauer C, Victorson D, Poli E, Smith TW, **Kopkash K**, **Yao K**, **Pesce C**. Exploring Breast Surgeons' Attitudes on Universal Genetic Testing: A Qualitative Study. *Ann Surg Oncol*. 2023 Oct;30(10):6108-6116. doi: 10.1245/s10434-023-13895-5. Epub 2023 Jul 13. PMID: 37439952

Lapkus M, **Pesce C**. Surgical Management of High-Risk Breast Lesions. *Difficult Decisions in Surgery: An Evidence-Based Approach*. *Difficult Decisions in Surgical Oncology*. Springer. 2023. In press

Lee JW, Hruban RH, Brosens LAA, Condello V, Nikiforova MN, Singhi AD, Pancreatic Cyst Alliance (**Hogg**). RNA Sequencing Identifies Frequent Mitogen-Activated Protein Kinase-Associated Fusion Genes in Intraductal Tubulopapillary Neoplasms of the Pancreas. *Gastroenterology*. 2023 Jun;164(7):1310-1313.e6. doi: 10.1053/j.gastro.2023.02.006. Epub 2023 Feb 17. PMID: 36801389

Mai PL, Miller A, Black A, Falk RT, Boggess JF, Tucker K, Stuckey AR, **Rodriguez GC**, Wong C, Amatruda TT, Wilkinson KJ, Modesitt SC, Yamada SD, Bixel KL, Glaser GE, Rose PG, Greene MH, Sherman ME. Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study. *Am J Obstet Gynecol*. 2022 Jul; 227(1):61.e1-61.e18. doi: 10.1016/j.ajog.2022.02.022. Epub 2022 Feb 22. PMID: 35216968

Meyyappan T, Wilson GC, Zeh HJ, **Hogg ME**, Lee KK, Zureikat AH, Paniccia A. Robotic approach mitigates the effect of major complications on survival after pancreaticoduodenectomy for periampullary cancer. *Surg Endosc*. 2022 Sep 26. doi: 10.1007/s00464-022-09638-4. PMID: 36163566

Moore AE, **Alvi SA**, Tarabichi O, Zhu VL, Buchakjian MR. Role of Lymphovascular Invasion in Oral Cavity Squamous Cell Carcinoma Regional Metastasis and Prognosis. *Ann Otol Rhinol Laryngol*. 2023 Nov 5;34894231211116. doi: 10.1177/00034894231211116. Online ahead of print. PMID: 37927046

Morgans AK, Chen YH, Jarrard DF, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, Dreicer R, Vogelzang NJ, Picus J, **Shevrin D**, Hussain M, DiPaola RS, Cella D, Sweeney CJ; ECOG-ACRIN E3805 Investigators. Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHARTED E3805. *Prostate*. 2022 Sep;82(12):1176-1185. doi: 10.1002/pros.24369. Epub 2022 May 10. PMID: 35538398

Mungo B, Hammad A, AIMasri S, Dogeas E, Nassour I, Singhi AD, Zeh HJ 3rd, **Hogg ME**, Lee KKW, Zureikat AH, Paniccia A. Pancreaticoduodenectomy for benign and premalignant pancreatic and ampullary disease: is robotic surgery the better approach? *Surg Endosc*. 2022 Sep 22. doi: 10.1007/s00464-022-09632-w. PMID: 36138252

Nicholson K, Bleicher R, Stevens R, Dietz J, Wilke L, Kurtzman S, Sarantou T, **Yao K**. Impact of the National Accreditation Program for Breast Center's Reconstruction Standard on Reconstruction Rates at Commission on Cancer Centers with Breast Center Accreditation. *Ann Breast Surg*. 2023 (accepted)

Nicholson K, Kuchta K, **Fefferman M**, **Pesce D**, **Kopkash K**, **Poli E**, **Yao K**. Trends in Bilateral Mastectomy Rates Among Different Racial Backgrounds: A National Cancer Database Study. *Am J Surg*. 2023 Oct;226(4):455-462.

Nicholson K, Kuchta K, **Pesce C, Kopkash K, Chichura A, Yao KA**. Impact of Surgical Delays During the Initial Surge of the COVID-19 Pandemic on Patients with Breast Cancer. *Ann Surg Oncol*. 2023; 30(2):691-693. PMID: 36484903

Oluymi ET, Grimm LJ, Goldman L, Burlison J, Simanowith M, **Yao K**, Rosenberg RD. Rate and timeliness of diagnostic evaluation and biopsy following recall from screening mammography in the National Mammography Database. *J of the Am Coll Radiol*. 2023 (accepted)

Paintal A, Antic T. The emerging role of NF2 alterations in new and established subtypes of renal cell carcinoma. *Hum Pathol*. 2023 Mar;133:87-91. doi: 10.1016/j.humpath.2022.06.008. Epub 2022 Jun 12. PMID: 35705112

Paniccia A, Polanco PM, Boone BA, Wald AI, McGrath K, Brand RE, ... **Hogg M**, et al. Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts. *Gastroenterology*. 2023 Jan;164(1):117-133.e7. doi: 10.1053/j.gastro.2022.09.028. Epub 2022 Oct 6. PMID: 36209796

Patel KR, Wang B, Abdelhamid Ahmed AH, Okose OC, Ma H, Behr IJ, Cheung AY, Saito Y, Kamani D, **Silver Karcioğlu A**, Liddy W, Takami H, Cunnane M, Randolph GW. Surgical and Biochemical Outcomes in Nerve Monitored Reoperation Surgery for Recurrent Papillary Thyroid Carcinoma. *Otolaryngol Head Neck Surg*. 2023 May 28. doi: 10.1002/ohn.389. Online ahead of print. PMID: 37245079

Perri G, van Hilst J, Li S, Besselink MG, **Hogg ME**, Marchegiani G. Teaching modern pancreatic surgery: close relationship between centralization, innovation and dissemination of care. *BJS Open*. 2023 Sep 5;7(5):zrad081. doi: 10.1093/bjsopen/zrad081. PMID: 37698977

Pesce CE. Donor Egg, Surrogacy and Adoption for Breast Cancer Survivors. *Current Breast Cancer Reports*. 2023 Feb;15:24-29

Pesce CE. Male Breast Mass. *Clinical Scenarios in Surgery*, 3rd Edition. Lippincott Williams & Wilkins. 2023. In press

Poli E, Chang C, Bleicher RJ, Moran M, Dietz J, Sarantou T, Kurtzman S, **Yao K**. Physician's Comfort Level with Observing Ductal Carcinoma In Situ of the Breast: A Survey of Breast Specialists at Accredited Breast Centers in the United States. *Ann Breast Surg*. 2023 (accepted)

Prinz RA, Talamonti MS, Hogg ME, Vining CC, MacKinney EC. Surgery for Glucagonoma. In: *Operative Techniques in Surgery*. Chapter 63, p. 1813-1828. 2nd Edition. Eds. Hawn MT, Pryor Ad, Hughes SJ, Albo D, Sabel MS, Brown KB, Goldberg AJ. Wolters Kluwer, Philadelphia, 2023

Raviv J, Sweis A. Survey of In-Office Rhinology and Skull Base Questionnaires. Accepted in 11/2022. *ARS COSM*. May 2023

Reitano E, Famularo S, Dallemagne B, Mishima K, Perretta S, Riva P, Addeo P, Asbun HJ, Conrad C, Demartines N, Fuks D, Gimenez M, **Hogg ME**, Lin CC, Marescaux J, Martinie JB, Memeo R, Soubrane O, Vix M, Wang X, Mutter D. Educational Scoring System in Laparoscopic Cholecystectomy: Is It the Right Time to Standardize? *Medicina (Kaunas)*. 2023 Feb 23;59(3):446. doi: 10.3390/medicina59030446. PMID: 36984446

Rifkin AS, Less EM, Wei J, Shi Z, Zheng SL, **Helfand BT, Hulick PJ, Krantz SB, Xu J**. Association of Reported Candidate Monogenic Genes with Lung Cancer Risk. *Clin Lung Cancer*. 2023 Jun;24(4):313-321

Rojas A, Paterakos P, **Talamonti MS, Hogg ME**. Robotic pancreaticoduodenectomy for intraductal papillary mucinous neoplasm in a patient post Roux-en-Y gastric bypass. *Obes Surg*. 2023 Feb 6. doi: 10.1007/s1169-023-06479-5. PMID: 36745332

Rojas A, Wodskow J, **Hogg ME**. Adult Pancreatoblastoma: a Rare Pancreatic Tumor. *J Gastrointest Surg*. 2023 Aug 24. doi: 10.1007/s11605-023-05816-4. Online ahead of print. PMID: 37620658

Russell MD, Shonka DC Jr, Noel J, **Karcioğlu AS**, Ahmed AH, Angelos P, Atkins K, Bischoff L, Buczek E, Caultley L, Freeman J, Kroeker T, Liddy W, McIver B, McMullen C, Nikiforov Y, Orloff L, Scharpf J, Shah J, Shaha A, Singer M, Tolley N, Tuttle RM, Witterick I, Randolph GW. Preoperative Evaluation of Thyroid Cancer: A Review of Current Best Practices. *Endocr Pract*. 2023 May 24:S1530-891X(23)00416-0. doi: 10.1016/j.eprac.2023.05.009. Online ahead of print. PMID: 37236353

Saulsberry L, Singh L, Pruitt J, Ward C, **Wake DT**, Gibbons RD, Meltzer DO, O'Donnell PH, **Cruz-Knight W, Hulick PJ, Dunnenberger HM**, David SP. Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System. *J Pers Med*. 2022 Jul 15;12(7):1145

Schwartz JL, Kuchta KM, Rojas A, Mehdi S, Hoon Choi S, Keutgen XM, **Talamonti MS, Hogg ME**. Number of hepatic resections and association with complications after metastatic neuroendocrine tumor debulking: An American College of Surgeons NSQIP Database Study. *J Am Coll Surg*. 2023 Jul 1;237(1):157-168. doi: 10.1097/XCS.0000000000000701. Epub 2023 Apr 4. PMID: 37022773

Scott BL, Sekeres MA, Garcia-Manero G, **Grinblatt DL**, DeGutis IS, Kiselev P, ... Roboz GJ. Implications for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic: A Connect Myeloid Registry study. *J Clin Oncol*. 2023; 41:16_suppl, 7021-7021

Sehnm L Jr, Noureldine SI, Avci S, Isikts G, Elshamy M, Saito Y, Ahmed AHA, Tierney HT, Trinh LN, **Karcioğlu AS**, Cheung AY, Otremba M, Krishnamurthy V, Heiden K, Jin J, Shin J, Siperstein A, Zafereo M, Tufano RP, Randolph GW, Kebebew E, Milas M, Duh QY, Berber E. A multicenter evaluation of near-infrared autofluorescence imaging of parathyroid glands in thyroid and parathyroid surgery. *Surgery*. 2023 Jan;173(1):132-137. doi: 10.1016/j.surg.2022.07.057. Epub 2022 Oct 28. PMID: 36511281

Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, **Helfand BT**, Eeles RA, Morgan TM. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. *Eur Urol*. 2023 Mar;83(3):241-248. doi: 10.1016/j.eururo.2022.12.021. Epub 2023 Jan 4. PMID: 36609003 Review

Sekeres MA, Garcia-Manero G, **Grinblatt DL**, Komrokji RS, Savona MR, Erba HP, ... Scott BL (2022). Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes. *Blood*. 2022; 140(Supplement 1), 9818-9820

Shi Z, Wei J, Rifkin AS, Wang CH, Billings LK, Woo JSH, Talamonti MS, Vogel TJ, Moore E, Brockstein BE, Khandekar JD, Dunnenberger HM, Hulick PJ, Duggan D, Zheng SL, Lee CJ, Helfand BT, Tafur AJ, Xu J. Cancer-associated thrombosis by cancer sites and inherited factors in a prospective population-based cohort. *Thromb Res*. 2023 Sep;229:69-72. doi: 10.1016/j.thromres.2023.06.023. Epub 2023 Jun 26. PMID: 37419004

Sisco M, Kuchta K, Alva D, Pruitt J, **Seth AK**. Oral antibiotics do not prevent infection or implant loss after immediate prosthetic breast reconstruction: Evidence from 683 consecutive reconstructions without prophylaxis. *Plast Reconstr Surg*. In Press.

continued >

Shi Z, Zhan J, **Wei J**, Ladson-Gary S, Wang CH, **Hulick PJ**, Zheng SL, Cooney KA, Isaacs WB, **Helfand BT**; 23andMe Research Team; Koelsch BL, **Xu J**. Reliability of Ancestry-Specific Prostate Cancer Genetic Risk Score in Four Racial and Ethnic Populations. *Eur Urol Open Sci*. 2022 Sep 17;45:23-30

Silver Karcioglu A, Abdelhamid Ahmed AH, Feng Z, Russell M, Shonka DC Jr, Iwata A, Cabanillas M, Shin JJ, Kyriazidis N, Park JC, Wirth LJ, Zafereo ME, Randolph GW. Return of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced Thyroid Cancer and Vocal Fold Paralysis: The Lazarus Effect. *Thyroid*. 2023 Sep 11. doi: 10.1089/thy.2023.0136. Online ahead of print. PMID: 37694677

Silver Karcioglu A, Triponez F, Solórzano CC, Iwata AJ, Abdelhamid Ahmed AH, Almqvist M, Angelos P, Benmiloud F, Berber E, Bergenfelz A, Cha J, Colaianni CA, Davies L, Duh QY, Hartl D, Kandil E, Kim WW, Kopp PA, Liddy W, Mahadevan-Jansen A, Lee KD, Mannstadt M, McMullen CP, Shonka DC Jr, Shin JJ, Singer MC, Slough CM, Stack BC Jr, Tearney G, Thomas G, Tolley N, Vidal-Fortuny J, Randolph GW. Emerging Imaging Technologies for Parathyroid Gland Identification and Vascular Assessment in Thyroid Surgery: A Review from the American Head and Neck Society Endocrine Surgery Section. *JAMA Otolaryngol Head Neck Surg*. 2023 Mar 1;149(3):253-260. doi: 10.1001/jamaoto.2022.4421. PMID: 36633855

Slonim LB, **Mangold KA**, **Alikhan MB**, **Joseph N**, **Reddy KS**, **Sabatini LM**, **Kaul KL**. Cell-Free Nucleic Acids in Cancer: Current Approaches, Challenges and Future Directions. *Clin Lab Med*. 2022 Dec;42(4):669-686. doi: 10.1016/j.cl.2022.09.017. PMID: 36368789 Review

Sood D, Kuchta K, Paterakos P, Schwarz JL, Rojas A, Choi SH, Vining CC, **Talamonti MS**, **Hogg ME**. Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the minimally invasive approach. *J Surg Oncol*. 2023 Mar;127(3):413-425. doi: 10.1002/jso.27135. Epub 2022 Nov 11 PMID: 36367398

Spurr LF, Martinez CA, Katipally RR, Iyer SC, Pugh SA, Bridgewater JA, Primrose JN, Domingo E, Maighan TS, D'Angelica MI, **Talamonti MS**, Posner MC, Connell PP, Weichselbaum RR, Pitroda SP. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. *NPJ Precis Oncol*. 2022 Oct 14;6(1):72. doi: 10.1038/s41698-022-00318-z. PMID: 36241710

Tomlinson B, de Lima M, Cogle CR, Thompson MA, **Grinblatt DL**, Pollyea DA, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, Abedi M, Garcia-Manero G, Kurtin SE, Maciejewski JP, Patel JL, Revicki DA, George TI, Flick ED, Kiselev P, Louis CU, DeGutis IS, Nifenecker M, Erba HP, Steensma DP, Scott BL. Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. *Transplant Cell Ther*. 2023 Jul;29(7):460.e1-460.e9. doi: 10.1016/j.jtct.2023.04.011. Epub 2023 Apr 21. PMID: 37086851

van den Broek BLJ, Zwart MJW, Bonsing BA, Busch OR, van Dam JL, de Hingh IHJT, **Hogg ME**, Luyer MD, Mieog JSD, Stibbe LA, Takagi K, Tran TCK, de Wilde RF, Zeh HJ 3rd, Zureikat AH, Groot Koerkamp B, Besselink MG; Dutch Pancreatic Cancer Group. Video Grading of Pancreatic Anastomoses During Robotic Pancreatoduodenectomy to Assess Both Learning Curve and the Risk of Pancreatic Fistula: A Post Hoc Analysis of the LAELAPS-3 Training Program. *Ann Surg*. 2023 Nov 1;278(5):e1048-e1054. doi: 10.1097/SLA.0000000000005796. Epub 2023 Jan 20. PMID: 36727842

van Ramshorst TME, van Hilst J, Bannone E, Pulvirenti A, Asbun HJ, Boggi U, Busch OR, Dokmak S, Edwin B, **Hogg ME**, Jang JY, Keck T, Khatkov I, Kohan G, Kokudo N, Kooby DA, Nakamura M, Primrose JN, Siriwardena AK, Toso C, Vollmer CM, Zeh HJ, Besselink MG, Abu Hilal M. International survey on opinions and use of robot-assisted and laparoscopic minimally invasive pancreatic surgery: 5-year follow-up. 2022 First Internationally Validated European Guidelines Meeting on Minimally Invasive Pancreatic Surgery and the IHPBA Innovation and Research Committees. *HPB (Oxford)*. 2023 Sep 6:S1365-182X(23)01923-8. doi: 10.1016/j.hpb.2023.09.004. Online ahead of print. PMID: 37739876

Victorson D, Morgan T, Kutikov A, **Novakovic K**, Kundu S, **Horowitz B**, **Jackson K**, **Addington E**, **Murphy K**, **Sauer C**, **Brendler C**. Mindfulness-based stress reduction for men on active surveillance for prostate cancer and their spouses: Design and methodology of a randomized controlled trial. *Contemp Clin Trials*. 2023 Feb;125:107059. doi: 10.1016/j.cct.2022.107059. Epub 2022 Dec 21. PMID: 36563902

Vinning CC, Al Abbas AI, **Kuchta K**, Paterakos P, Choi SH, **Talamonti MS**, **Hogg ME**. Risk factors and outcomes in patients undergoing minimally invasive hepatectomy with unplanned conversion: a contemporary NSQIP analysis. *HPB (Oxford)*. 2023 Feb 2; S1365-182X(23)00031-X. doi: 10.1016/j.hpb.2023.01.018. PMID: 36868951

Woodhouse B, Barreto SG, Soreide K, Stavrou GA, Teh C, Pitt H, Di Martino M, Herman P, Lopez-Lopez V, Berrevoet F, **Talamonti M**, et al. A core set of quality performance indicators for HPB procedures: a global consensus for hepatectomy, pancreatectomy and complex biliary surgery. *HPB (Oxford)*. 2023 Aug;25(8):924-932. doi: 10.1016/j.hpb.2023.04.009. Epub 2023 Apr 27. PMID: 37198070

Xu J, Resurreccion WK, Shi Z, Wei J, Wang CH, Zheng SL, **Hulick PJ**, Ross AE, Pavlovich CP, **Helfand BT**, Isaacs WB. Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. *Prostate Cancer Prostatic Dis*. 2022 Sep;25(3):422-430

Zeidan AM, Gautam S, Yu R, Lan Z, **Grinblatt DL**, ElSouda D, ... Pandya BJ. Streamline-Retrospective Cohort Study of FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes After First Relapse or Refractory (R/R) Diagnosis. *Blood*. 2022; 140 (Supplement 1), 8124-8126

Zijlstra MK, Gampa A, Joseph N, Sonnenberg A, **Fimmel CJ**. Progressive changes in platelet counts and Fib-4 scores precede the diagnosis of advanced fibrosis in NASH patients. *World J Hepatol*. 2023 Feb 27;15(2):225-236. doi: 10.4254/wjh.v15.i2.225. PMID: 36926233; PMCID: PMC10011908

Zwart MJW, van den Broek B, de Graaf N, Suurmeijer JA, Augustinus S, Te Riele WW, van Santvoort HC, Hagendoorn J, Borel Rinkes IHM, van Dam JL, Takagi K, Tran TCK, Schreinemakers J, van der Schelling G, Wijsman JH, de Wilde RF, Festen S, Daams F, Luyer MD, de Hingh IHJT, Mieog JSD, Bonsing BA, Lips DJ, Hilal MA, Busch OR, Saint-Marc O, Zeh HJ 3rd, Zureikat AH, **Hogg ME**, Koerkamp BG, Molenaar IQ, Besselink MG; Dutch Pancreatic Cancer Group. The Feasibility, Proficiency and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program: Standing on the Shoulders of Giants. *Ann Surg*. 2023 Jun 8. doi: 10.1097/SLA.0000000000005928. Online ahead of print. PMID: 37288547



2023 Academic Leadership Roles and Awards

Kellogg Cancer Center clinicians are active in a broad range of regional and national organizations.

Sameer Alvi, MD

- American Head & Neck Society—Member, Young Members Service
- American Head & Neck Society—Member, Website and Social Media Service
- Peer Reviewer, *Annals of Otolaryngology, Rhinology and Laryngology*

Poster Presentation:

- Utility and Validity of Preoperative Positron Emission Tomography (PET) in Localizing Perforator Vessels of Anterolateral Thigh Free Flap. McMillan A, **Alvi SA**, Al-Qurayshi Z, Fleischacker Z, Pagedar N, Buchakjian M. Poster Presentation, AHSN International Meeting, July 2023, Montreal, QC, Canada

Bruce Brockstein, MD

- Member, Head and Neck Committee, Eastern Cooperative Oncology Group

Editorial:

- *UpToDate* (Online Textbook), Chapter Editor, *Head and Neck Cancer*, 2000–present

Awards:

- *Chicago Magazine* Top Doctors

Nicholas Campbell, MD

Editorial:

- Reviewer: *Lung Cancer, Clinical Case Reports*

Kim Cholewa, MSN, RN, MEDSURG-BC, CHPN

- Completed ANCC NEA-BC specialty certification

Nisha Desai, MD

- Dermatology Lead, Family Medicine Lecture Series

Poster Presentation:

- “Necrobiosis Lipoidica Like Dermal Presentation Secondary to Sclerotherapy,” American Society of Dermatopathology Meeting, 2023. Mehreen A, Abdelsadek O, **Desai N**, Cibull T

Claus Fimmel, MD, CPE

- Advisory Board, American Liver Foundation, Chicago Chapter, 2008–present

Editorial:

- Reviewer: *Hepatology, American Journal of Gastroenterology, American Journal of Physiology, Journal of Hepatology, Journal of Laboratory and Clinical Investigation, Laboratory Investigation, American Journal of Pathology, Oncogene, Gastroenterology, Clinical Gastroenterology and Hepatology, Journal of Cellular Biochemistry, Journal of Proteome Research, Proceedings of the National Academy of Sciences, PLOS Medicine, ACG Case Reports Journal, World Journal of Hepatology*

Nancy Flowers, LCSW

- NHPCO (National Hospice and Palliative Care Organization): Member of the NHPCO Executive Committee and Section Leader, MyNHPCO Social Work Community; presented at NHPCO’s annual Leadership and Advocacy Conference in October 2022 and October 2023

- Guest lecturer, Loyola University School of Social Work
- Other community education: Cancer Wellness Center, NorthShore Senior Center, CJE Senior Life, Lutheran Home, others
- Board Membership: Bishop Anderson House, Three Crowns Park (past Board Chair for both)

David Grinblatt, MD

- Community Oncology Committee, ALLIANCE for Clinical Trials in Oncology, 2010–present
- Principal Investigator, Alliance for Clinical Trials in Oncology
- Scientific Advisory Committee, Connect MDS/AML Registry and Connect[®] Lymphoma Disease Registry

Brian Helfand, MD, PhD

- Guideline Review Committee for American Urological Association Prostate Cancer Early Detection
- Guidelines Committee Member: American Urological Association Overactive Bladder
- American Urological Association North Central Research Committee
- Established race-specific genetic testing for prostate cancer in collaboration with GoPath Diagnostics
- Principal Investigator: Blue Earth Diagnostics Study on PSMA Imaging Techniques
- Principal Investigator: NanoKnife IRE PRESERVE trial (focal therapy for prostate cancer)
- Grand Rounds: Changes in imaging techniques for Prostate Cancer Staging and Recurrence: UCSD, Invited Speaker
- Current Updates in Prostate Cancer; UsToo Prostate Cancer Support Group
- Grand Rounds in Urology Series: Prostate cancer imaging—a patient discussion
- Grand Rounds in Urology: Invited Speaker for Future of Genomic Testing in Urology

Thomas Hensing, MD

- Respiratory Health Association, Lung Cancer Initiative Advisory Council, 2005–present
- ALLIANCE for Clinical Trials in Oncology, Respiratory Committee Member, 2010–present
- CoC/NCDB Lung Quality Measures Group, 2011–Present
- Respiratory Health Association, Invited Member, Scientific Advisory Committee, 2019–Present

Melissa Hogg, MD

- Education Council (2020–present), Chair (2022–2024), Executive Council (2023–2026)—SSO (Society of Surgical Oncology)
- Membership Committee (2020–2023)—SUS (Society of University Surgeons)
- Alliance Executive Board Liaison (2020–2023), CSSP Representative (2023–present)—AHPBA (American Hepato-Pancreato-Biliary Association)
- HPB Task Force (2017–present), Co-Chair (2019–present), Oncology Task Force (2020–present)—SAGES (Society of American Gastrointestinal and Endoscopic Surgeons)

- Fellowship Council—HPB working group representing SAGES (Society of Gastrointestinal and Endoscopic Surgeons)

Awards:

- Distinguished Alumni Award, U Pitt Medical Education, 2023
- University of Chicago—Teaching Award, 2022–2023

Invited Lectures:

- “Resident Robotic Training: The Past, The Present, The Future” Grand Rounds @ SUNY April 2023
- “Video-Based Assessment: Eliminating Bias” Women in Surgery Career Symposium. Clearwater, FL. February 2023
- “Regrettable Decisions: MIS” AHPBA March 11, 2023, Miami, FL
- “MIS Biliary Updates” March 12, 2023, Miami, FL
- “Career Panel: Community vs. Academic Practice” SSO March 22, 2023, Boston, MA
- “Advanced Simulation Based Training Program for Robotic Surgery: Robotic Pancreaticoduodenectomy” Mayo Robotic Conference April 15, 2023, Orlando, FL
- “DGE – Professor Talk” DDW May 8, 2023, Chicago, IL
- “How We Educate Our Fellows” SSAT-SAGES Joint Symposium, May 8, 2023
- “Surgical Education: Robotics, Simulation, and Beyond,” Northwell Medical School Curriculum ReCamp, May 2023
- “Robotic Pancreatectomy: Oncologic Outcomes and Clinical Trials,” CRSA September 2023. Chicago IL
- “Pancreatoduodenectomy Reconstruction Masterclass,” LEARNBOT Europe April 11, 2023
- “Robotic Gastrointestinal and HPB Surgery: Learning Curve, Educational Programs and Outcomes,” Rome, Italy, May 2023
- “Simulation Based Training Program for HPB Robotic Surgery,” Society of Robotic Surgery (SRS) June 2023 Melbourne, Australia
- “How I do It—Pancreatic Head Resection” SRS June 2023, Melbourne, Australia
- “How I do It—Pancreatic and Biliary Anastomosis” SRS June 2023, Melbourne, Australia
- “Retropertitoneal Dissection in Robotic Pancreatoduodenectomy: How I Do It,” Society of Italian Surgery. Pisa, Italy. September 2023
- “Training the Future Surgeon,” Pisa, Italy. September 2023

Editorial Boards:

- Editorial Board (Pancreas), *Annals of Surgical Oncology*, (2020–present)
- Associate Editor, Surgical Technique Division, *Journal of Surgical Oncology* (2015–present)
- Editorial Board (Pancreas), HPB (2021–present)
- Peer Reviewer: *Annals of Surgery, Annals of Surgical Oncology, Journal of Surgical Oncology, Journal of GI Surgery, HPB, Surgery, Journal of Surgical Research, Journal of Surgical Education, Surgical Endoscopy, British Journal of Surgery, JAMA Surgery, Archives of Surgery, Journal of the American College of Surgeons, World Journal of Surgery, Lancet Gastroenterology*

continued >

Peter J. Hulick, MD, MMSc, FACMG

- American College of Medical Genetics and Genomics representative on the CancerLinQ Oncology Leadership Council for ASCO
- Epic Genetics and Genomics Steering Board Member
- Member—Personalized Medicine Coalition Public Policy Committee
- Member—Personalized Medicine Coalition Science Policy Committee
- Director on the American Board of Medical Genetics and Genomics

Awards:

- Newly appointed as the Janardan D. Khandekar MD, Chair of Personalized Medicine, NorthShore University HealthSystem

Poster Presentation:

- Hulick P, Choi S, Dunnenberger H, DePersia A. Integrating Family Health History Screening and Genetic Testing via Electronic Health Record with Clinical Decision Support in Routine Screening Mammography. Poster presentation at the American College of Medical Genetics and Genomics Meeting, Nashville, TN, 2022

Presentations:

- 2022: Panelist: “Precision Medicine—Beyond the “One-Size-Fits-All” Model.” Kellogg Business of Healthcare Conference, Evanston, IL
- 2022: Lessons Learned from Virtual Genetic Counseling. Precision Medicine World Conference 2022, Silicon Valley, CA
- 2022: Keynote Speaker: “The State of Genomic Learning Healthcare Systems.” NHGRI Genomic Medicine XIV: Genomic Learning Healthcare Systems 2022
- 2022: “Population Genetic Screening Efforts in Primary Care.” Precision Oncology and Diagnostics Conference, Chicago, IL
- 2023: “Improving Access to Genetics Through Primary Care.” AGBT Precision Health Meeting, San Diego, CA

Amanda Silver Karcioglu, MD

National Committees:

- Patient Care and Education Committee of the American Head and Neck Society—Endocrine Surgery Section
- Scientific Review Committee for 11th International Conference on Head & Neck Cancer, July 8-12, 2023 in The Palais des Congrès, Montréal, QC Canada

National Presentations:

- Great Debate: Is Parathyroid Autofluorescence the New Operative Standard for Thyroid Surgery? (Presenter), AAO-HNSF 2023 Annual Meeting and Oto Experience Nashville, TN, September 30-October 4, 2023
- Parathyroid Gland Identification: More Than Meets the Eye(Presenter), AAO-HNSF 2023 Annual Meeting and Oto Experience Nashville, TN, September 30-October 4, 2023
- Surgical Recurrent Laryngeal Nerve Variability and Risk of Injury (Presenter). AAO-HNSF 2023 Annual Meeting and Oto Experience Nashville, TN, September 30-Oct 4, 2023

- Scientific Oral Presentations—Head and Neck/Endocrine Surgery (Moderator), AAO-HNSF 2023 Annual Meeting & OTO EXPO, Nashville, TN, September 30-October 4, 2023
- Outcomes Regarding Hypoparathyroidism and the Future Regarding Treatment of Hyperparathyroidism (Presenter), American Head and Neck Society 11th International Conference on Head and Neck Cancer, Montreal, Canada, July 8-12, 2023
- Autofluorescence and Fluorescent Angiography Case Presentations (Panelist), American Head and Neck Society 11th International Conference on Head and Neck Cancer, Montreal, Canada, July 8-12, 2023
- Near-Infrared Autofluorescence Technology in Thyroid Surgery—Video Session (Presenter), American Head and Neck Society 11th International Conference on Head and Neck Cancer, Montreal Canada July 8-12, 2023
- Intraoperative Nerve Monitoring (IONM)—Guidelines, Troubleshooting and Pearls (Presenter), American Head and Neck Society 11th International Conference on Head and Neck Cancer, Montreal, Canada, July 8-12, 2023
- Scientific Review Committee, American Head and Neck Society 11th International Conference on Head and Neck Cancer, Montreal, Canada, July 8-12, 2023
- Intraoperative Nerve Monitoring in Thyroid Surgery (Presenter), World Congress on Thyroid Cancer, London, UK, June 14-18, 2023
- Tumor Board: Thyroid Cancer Cases (Panelist), World Congress on Thyroid Cancer, London, UK, June 14-18, 2023
- Advanced Training in Endocrine Surgery Thyroid Endocrine Oncology: A Session for Endocrinologists and Surgeons (Panelist), World Congress on Thyroid Cancer, London, UK, June 14-18, 2023
- Masters Video Session (Panelist), World Congress on Thyroid Cancer, London, UK, June 14-18, 2023
- Neoadjuvant Treatment for Advanced Thyroid Cancer: Sydney-Boston Neoadjuvant Implementation Algorithm. Russell MD, Gild ML, Wirth LJ, Robinson BG, **Silver Karcioglu A**, Iwata AJ, Abdelhamid Ahmed AH, Randolph GW. Oral presentation at the World Congress on Thyroid Cancer (WCTC), London, UK, June 15-17, 2023
- A Phase II study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer. Kyriazidis N, Russell MD, Abdelhamid Ahmed AH, **Silver Karcioglu A**, Sherman EJ, Ho AL, Fagin JA, Wong RJ, Busaidy NL, Zafereo ME, Sadow P, Park JC, Wirth LJ, Randolph GW. Accepted as an oral presentation at the World Congress on Thyroid Cancer (WCTC), London, UK, June 15-17, 2023 (Winner of Oral Podium Presentation Award)
- Parathyroid Autofluorescence White Paper and Videos (Presenter), Parathyroid Autofluorescence Equipment and Literature Review (Presenter), External Branch of the Superior Laryngeal Nerve (EBSLN) (Presenter) Radiofrequency Ablation Billing (Presenter), Endocrine Surgery Technology Course. Mass General Brigham, Mass Eye and Ear, Harvard Medical School, Boston, MA, November 4-5, 2022

Karen Kaul, MD

National Committees:

- American Board of Pathology: Appointed Trustee, 2011-present, Chair, Test Development & Advisory Committee for Molecular Genetics, 2012-present, Maintenance of Certification Committee, 2012-present, Credentials Committee, 2012-present, Communications Task Force, 2012-present
- Association for Molecular Pathology: Chair, MGP Curriculum Update (MGPCUP) committee, 2019-present, AMP COVID Response (ACR) Steering Committee, 2020-present, Member, JMD Editor in Chief Selection Committee, 2021-present
- College of American Pathologists: Member, Executive Advisory Board, Archives of Pathology & Laboratory Medicine, 2015-present
- Association of Pathology Chairs: Chair, ad hoc Clinical Service Leaders Council, 2021-present, Vice Chair, Advocacy Committee, 2021-present

Scientific Review Activities:

- Ad Hoc Member, NIH/NCI P01 reviewer, 2001-present, SBIR Review Panels, various, 2008-present; Panel chairperson 2010-present; Peer Reviewer, Prostate Cancer Foundation, 2010-present; Peer Reviewer, University of Chicago CTSA Pilot Program, 2011-present; Chair, NorthShore Auxiliary Breast/Ovarian Research Program, 2013-present

Other National Activities:

- Lab 2.0 Board Member, 2019-present
- Member, CLIA CLIA Regulations Assessment Workgroup, 2021-present

Editorial:

- Ad Hoc Reviewer: *American Journal of Clinical Pathology*, *Archives of Pathology and Laboratory Medicine*, *Cancer*, *Cell Growth and Differentiation*, *Chest*, *Clinical Chemistry*, *Clinical Microbiology Reviews*, *Pediatric Pathology*, *Tubercle*, 1990-present
- Editorial Board, *Annual Reviews in Pathology*, 2011-present
- Associate Editor, *Academic Pathology*, 2014-present
- Executive Advisory Board, *Archives of Pathology & Laboratory Medicine*, 2015-present

Invited Talks:

- Realizing the Potential of Genomics Across the Continuum of Precision Health Care. National Academy of Science, Engineering and Medicine, Roundtable on Genomics and Precision Health, Speaker and panelist.

Margaret Keller, APN

- Completed the University of Michigan’s Integrative Oncology Scholars program, June 2022

Poster Presentation:

- “The Time Is Now: Creating a Nurse-Practitioner-Led Integrative Oncology Clinic” at the Society of Integrative Oncology’s annual conference, Banff, Alberta, Canada in September 2023

Janardan D. Khandekar, MD

Editorial:

- Associate Editor, *Journal of Surgical Oncology*
- Reviewer, *PLOS Medicine* and *Journal of Clinical Oncology*

Grants:

- Anonymous FDN to sequential study titled “Immune Response to COVID Vaccination in Cancer Patients”

Honors:

- NorthShore has established The Janardan D. Khandekar, MD, endowed chair in Personalized Medicine in honor of Dr. Khandekar. This Chair recognizes the extraordinary 46-year legacy of Dr. Khandekar, who as the founder of the Division of Medical Oncology, Director of the NorthShore Kellogg Cancer Center for 25 years, and the Louise W. Coon Chairman of Medicine for 13 years has led the way to creating today’s program in genomics.

Katherine Kopkash, MD

- Vice President, Chicago Surgical Society
- Oncoplastics Committee, American Society of Breast Surgeons
- Principal investigator for the FDA-reviewed national trial “A Prospective, Multicenter Investigation of the da Vinci® Xi™ Surgical System in Nipple-Sparing Mastectomy (NSM) Procedures”

Awards:

- Alpha Omega Alpha Beta Chapter Class of 2023 at the Pritzker School of Medicine Volunteer Clinical Faculty Award, 2023
- Castle Connolly Top Doctor, 2023
- University of Chicago Excellence in Teaching Award from the Department of Surgery for 2018-19, 2020-2021, 2021-2022, 2022-2023 academic years
- NorthShore University HealthSystem Service Values Award 2018-present (26-time award winner, nominated for exceptional performance earning customer loyalty)

Seth Krantz, MD

- Chair, NorthShore University HealthSystem Cancer Committee
- Head, Division of Thoracic Surgery
- Clinical Associate Professor of Surgery, University of Chicago Pritzker School of Medicine

Committees:

- Society of Thoracic Surgeons, Health Policy and Advocacy Task Force Member
- American College of Surgeons Cancer Research Program Standards Investigation and Validation Committee Member
- Site PI, surgical research cooperative of the American Association for Thoracic Surgery
- Site PI for Prolonged Air Leak Autologous Blood Patch Intervention Trial

Awards:

- Outstanding Cancer Liaison Physician Award, American College of Surgeons Commission on Cancer
- University of Chicago Department of Surgery Excellence in Teaching Award 2022-2023

Editorial:

- Reviewer: *Annals of Surgical Oncology*, *Annals of Thoracic Surgery*, *Chest*, *Journal of Thoracic and Cardiovascular Surgery*

Robert Marsh, MD

- Eastern Cooperative Oncology Group, GI Committee

Editorial:

- Reviewer: *American Journal of Clinical Oncology*, *British Medical Journal*, *Cancer*, *Cancer Management and Research*, *Cell*, *European Journal of Surgical Oncology*, *Journal of Cancer Research and Clinical Oncology*, *Journal of Surgical Oncology*, *Journal of the Pancreas*, *Lancet Oncology*, *Public Library of Science*, *Rogers Medical Intelligence Solutions CME Programs*, *Southern Medical Journal*, *Therapeutic Advances in Gastroenterology*

Leslie Mendoza Temple, MD

- Co-Chair of the Oversight Committee for the International Research Congress for Integrative Medicine and Health, to be held in Cleveland, Ohio, in April 2024
- Co-investigator for an international Delphi study on Competency-Based Medical Education (CBME) for healthcare professionals on the subject of cannabis education for trainees with Mikhail Kogan, MD (George Washington University), Richard Israelowitz, PhD, and Yuval Zolotov, PhD (Both from Ben-Gurion University of the Negev in Israel)
- Member, Medical Cannabis Advisory Board, Illinois Department of Public Health

Catherine E. Pesce, MD

- Head, Division of Surgical Oncology
- Society of Surgical Oncology (SSO) Breast Surgical Oncology Fellowship Program Directors Committee

Leadership/Awards:

- American Society of Breast Surgeons (ASBrS) Online Video Library
- Excellence in Teaching Award from the University of Chicago Department of Surgery for 2022-2023
- Excellence in Teaching Award from the University of Chicago Department of Surgery for 2021-2022
- Breast Surgical Oncology Fellow Anna Chichura, MD, won the 2022 ASBrS Annual Meeting “Outstanding Scientific Presentation Award for the Best Presentation by a Fellow, Resident or Medical Trainee” for her oral podium presentation: “Male Breast Cancer Patient and Surgeon Experience: The Male WhySurg Study”

Committees:

- American Society of Breast Surgeons (ASBrS) Online Video Library Committee
- Society of Surgical Oncology (SSO) Breast Surgical Oncology Fellowship Program Directors Committee, 2021-present

Presentations:

- NorthShore Foundation Powered by Giving Event. “Personalized Medicine and Genomics as Ways to Make Breast Health and Cancer Screening Unique.” Wilmette, IL, 2023
- American Society of Breast Surgeons Annual Meeting. “Goldilocks Mastectomy; ASBrS Video Presentation How I Do It.” Boston, MA, 2023

Joseph Raviv, MD

- Chicago Laryngological & Otological Society —Immediate Past President
- American Rhinologic Society (ARS)—Rhinology Training Council, Co-Director Annual ARS Advanced Sinus and Skull Base Course
- *Chicago Magazine* Top Doctors

Sara Reynolds, APN

- Completed the University of Michigan’s Integrative Oncology Scholars program, June 2022

Poster Presentation:

- “The Time Is Now: Creating a Nurse-Practitioner-Led Integrative Oncology Clinic” at the Society of Integrative Oncology’s annual conference, Banff, Alberta, Canada in September 2023

Gustavo Rodriguez, MD

- Member, Cancer Prevention and Control Committee, Gynecologic Oncology Group/NRG, 1997-present
- Advisory Board, Gilda’s Club, Chicago, 2004-present

Editorial:

- Peer Reviewer: *American Journal of Obstetrics & Gynecology*, *Current Cancer Drug Targets*, *Gynecologic Oncology*, *Journal of Clinical Oncology*
- Peer Reviewer: *Journal of Clinical Oncology*

Presentations:

- Advances in Complex Thyroid Surgical Care (Presenter), Department of Medicine Grand Rounds, NorthShore University HealthSystem, Evanston, IL, April 21, 2023
- Advances in Complex Thyroid and Parathyroid Surgical Care (Presenter), Department of Medical Oncology Grant Rounds, NorthShore University HealthSystem, Evanston IL July 27, 2023

Carol Rosenberg, MD

- Mentor, Scholars in Oncology Associated Research Program (SOAR) at the University of Chicago Pritzker School of Medicine covering multidisciplinary and inter-professional aspects of oncology (cancer) research and clinical care. NIH/NCI grant 1R25CA240134-01
- Key Informant, Johns Hopkins University Evidence-Based Practice Center (EPC) and the Agency for Healthcare Research and Quality (AHRQ) Topic Refinement and Realist Reviewer on “Models of Pediatric-Adolescent-Adult Cancer Survivorship Care that include Primary Care”
- Reviewer, *ASCO Journal of Clinical Oncology (JCO) Oncology Practice*
- Research Investigator/Topic Reviewer, Women’s Health Initiative Study, National Institutes of Health (NIH NHLBI)

Awards:

- Myra Rubenstein Weis LIFE Program Grant Award Recipient to the MRW LIFE Cancer Survivorship program: Myra Rubenstein Weis Health Resource Center Foundation NorthShore University HealthSystem May, 2023

continued >

Poornima Saha, MD

Poster Presentations:

- Akmatbekov A, **Saha P**, DePersia A, and Sullivan M. Predicted and Genomic Risk in ER+ Invasive Breast Cancer in BRCA Mutation Carriers. Poster presented at United States and Canadian Academy of Pathology 2022 Annual Meeting. March 2022. Los Angeles, California
- DeLuna H, Velikov D, Patel H, Feld J, Robin J, Rosenberg C, and **Saha P**. Improving cardiac monitoring in early-stage breast cancer patients receiving cardiotoxic chemotherapy in a multidisciplinary cancer center. Poster presented at ASCO Quality Care Symposium. September 2022. Chicago, Illinois.
- Peterson J, Rubio J, Pandey T, the SimBioSys team, and **Saha P**. Validation of prognostic platform to further refine identification of high-risk patients indicated for chemotherapy-free treatment in early-stage breast cancer. Poster presented at San Antonio Breast Cancer Symposium (SABCS). December 2022. San Antonio, Texas.
- **Saha P**, Aller A, Deliere A, Kuchta K, Sullivan M, Hulick P, Yao K, and DePersia A. Application of 21-gene Breast Recurrence Score[®] assay to evaluate prognosis and benefit of adjuvant chemotherapy in BRCA1 and BRCA2 pathogenic variant carriers with early-stage, estrogen receptor positive breast cancer. Poster presented at San Antonio Breast Cancer Symposium (SABCS). December 2022. San Antonio, Texas.
- **Saha P**, Uy A, Thakkar P, Kuchta K, and Yao K. Trends in clinical treatment of early-stage ER+PR- breast cancer in the National Cancer Database. Poster presented at San Antonio Breast Cancer Symposium (SABCS). December 2022. San Antonio, Texas.
- Xu W, Shin S, Vickman R, Filimon B, Yang Y, Hu Z, Mangold K, Sullivan M, Kaul K, **Saha P**, **Khandekar J**, Prabhkar B, Schrieber H, Hayward S, Brockstein B, and Seth P. The safety and efficacy of the systemic delivery of a new liver-detargeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple-negative mouse mammary tumor model. Poster presented at 25th Annual Meeting of American Society of Gene & Cell Therapy (ASGCT).
- Chen N, Michaels E, **Saha P**, Rampurwala M, Hahn O, Howard F, Fleming G, Karrison T, Conzen S, and Nanda R. Phase II Study of Pembrolizumab plus Mifepristone in Patients with Advanced HER2-Negative Breast Cancer. Poster accepted American Society of Clinical Oncology (ASCO). June 2023. Chicago, Illinois.
- Chen N, **Saha P**, Rampurwala M, Kamaraju S, Hahn O, Howard F, Fleming G, Matossian M, Freeman J, Karrison T, Conzen S, Nanda R, and Stringer-Reasor E. A Randomized Phase II Trial of Nab-Paclitaxel with or without Mifepristone for Advanced Triple-Negative Breast Cancer. Poster accepted American Society of Clinical Oncology (ASCO). June 2023. Chicago, Illinois.

Awards:

- 2023 NorthShore Women's Cancers Research Program: Concept/Pilot Award Recipient – Dr. Poornima Saha for project entitled “Artificial Intelligence for Response Prediction in Breast Cancer.”

Principal Investigator:

- EA1181: Compass(HER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
- A011801: The CompassHER2 trials (Comprehensive use of Pathologic Response Assessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, Phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib
- S2007: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

Akhil Seth, MD

- Residency Site Director, Plastic and Reconstructive Surgery Residency, University of Chicago

Clinical Trials:

- Principal Investigator: The Safety and Effectiveness for DuraSorb for Lower Pole Reinforcement in Patients Undergoing 2-Stage Breast Reconstruction

Daniel Shevrin, MD

- Community Co-Chair, ECOG GU Committee, 2005-present
- Medical Director, NorthShore Chapter of US TOO Prostate Cancer Support Group, 2002-present
- Director, Advocacy Core Prostate SPORE, Northwestern University, 2003-present

Mark Sisco, MD, FACS

- Program Committee, Breast Subsection, American Society of Plastic Surgeons, 2015-present

Editorial:

- Editorial Board Member and Peer Reviewer, *Journal of Surgical Oncology*, 2014-present
- Peer Reviewer, *Journal of Surgical Research, Plastic and Reconstructive Surgery*

Mark Talamonti, MD

- Ex Officio Member, Medical Advisory Committee, PanCAN, Pancreatic Cancer Action Network, 2010-present
- High Risk GI Committee, member, American College of Surgeons Committee on Patient Safety and Improved Quality, 2018-present
- Chairman, Department of Surgery, NorthShore University HealthSystem, 2007-present

Awards:

- Outstanding Faculty Teacher Award, Department of Surgery, University of Chicago Pritzker School of Medicine
 - Castle and Connelly and *Chicago Magazine* Top Doctors in America and Chicago
 - *US News and World Report*: Top 1% of Surgeons in America
 - National Pancreas Foundation 2023 Legacy Award
- #### Presentations:
- Wisdom from Experience: Financial Stewardship in Preparation for Retirement. American Hepato-Pancreatic-Biliary Association (AHPBA) Meeting. Miami, Florida. March 9, 2023
 - Moving from Open to Robotic Pancreaticoduodenectomy. American Hepato-Pancreatic-Biliary Association (AHPBA) Meeting. Miami, Florida. March 10, 2023

Amy Wang, MD

- Fellowship Director, Division of Hematology/Oncology, NorthShore University HealthSystem

Presentations:

- Oral Presentation abstract #670: “New Onset Neurocognitive Impairment in Long-Term Survivors of Early Adolescent and Young Adult Hematologic Malignancies: A Report from the Childhood Cancer Survivor Study.” 65th ASH Annual Meeting, San Diego, CA, December 2023
- Poster Presentation abstract #3776: “Improved Neurocognitive Outcomes with Contemporary Treatments in Survivors of Early Adolescent and Young Adult Hematologic Malignancies from the Childhood Cancer Survivor Study.” 65th ASH Annual Meeting, San Diego, CA, December 2023

Lauren Wiebe, MD

- American College of Surgeons Cancer Research Program Standards Investigation and Validation Committee Member
- TPN in Cancer Patients Working Group, NorthShore, 2023-present

Editorial:

- Invited Peer-Reviewer: *Journal of Palliative Medicine*, 2021-2023

Katharine Yao, MD

- Member, ASCO-SSO Germline Mutation Testing in Breast Cancer Guideline Panel
- Practice Advocacy Committee, American Society of Breast Surgeons
- Member, Prevention Committee of the Alliance
- Chair, Breast Disease Site Group Quality Measures, Commission on Cancer
- Chair, National Accreditation Program for Breast Centers
- Chair, Benign Breast Pathway Steering Group, American Society of Breast Surgeons
- Member, Commission on Cancer Executive Committee
- Member, Executive Committee on Surgical Standards, Commission on Cancer, American College of Surgeons
- Co-Moderator, Management of Hormone Receptor Positive Breast Cancer in the Elderly, American College of Surgeons Clinical Congress, Boston, MA, October 2023
- Breast Cancer Research Foundation, Precision Prevention Initiative Grant Review Panel
- American Cancer Society National Breast Cancer Roundtable, Workgroup member for Risk Reduction, Screening and Early Detection Priority Workgroup

Awards:

- Masters in Healthcare Quality and Patient Safety, Northwestern University, June 2023

Editorial:

- Editorial Board: *Journal of Surgical Oncology, Annals of Surgical Oncology, Annals of Breast Surgery*

Grants:


- Mindfulness intervention and response to stress and quality of life in patients diagnosed with breast cancer. John Wayne Cancer Foundation Grant Award. Recipient, Principal Investigator: Yao K
- Developing Digital Pathology for Breast Cancer Recurrence, Department of Defense Grant. Principal Investigator: Huo D (UofC). Site Principal Investigator: Yao K



2023 Physician Directory



Matthew Adess, MD
Medical Director, Highland Park Kellogg Cancer Center
Expertise: GI Oncology; Benign and Malignant Hematology
Locations: GBK, HPK



Elizabeth Burke, MD
Expertise: Breast and Facial Reconstruction Including Facial and Breast Reconstruction; Microsurgery; Skin Cancer; Aesthetic Breast and Body Surgery
Locations: NMB, SW



Michael Dombrowski, MD
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK




Marc Alonzo, MD
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Nicholas Campbell, MD
Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers
Locations: EVK, HPK, SW



Thomas Farrell, MD
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK




Sameer Alvi, MD
Expertise: Head and Neck Cancers; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery
Locations: NMB, SW



Carolina Soto Chervin, MD
Expertise: Lung Cancer; GI Oncology
Locations: EVK, HPK



Claus Fimmel, MD
Expertise: Liver Diseases; Gastrointestinal Diseases; GI Endoscopy; Liver Biopsy
Locations: EVK, HPH, SK



Saad Arain, MD
Expertise: Benign and Malignant Hematology
Locations: GBK, HPK



Shakeel Chowdhry, MD
Expertise: Surgery for Aneurysms; Endovascular Treatment for Aneurysms; Arteriovenous Malformations (AVMs); Interventional Stroke Therapy; Brain Tumors; Pituitary Tumors; Spinal Tumors
Locations: EV, GB, NCH



Alla Gimelfarb, MD
Medical Director, Kellogg Cancer Center Immediate Care
Expertise: Benign and Malignant Hematology
Location: GBK



Hassan Arshad, MD
Expertise: Head and Neck Cancer; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery
Locations: EVK, NMB, SW



John Cieslak, MD
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



David Grinblatt, MD
Medical Director, Cell Therapy
Expertise: Benign and Malignant Hematology
Locations: EVK, GBK




Tariq Azam, MD
Expertise: Cancer-Related Cardiotoxicity; Cancer-Treatment Related Cardiotoxicity; General Cardiology; Preventive Cardiology; Cardiovascular Disease; Cardiac Imaging
Location: VH



Jeffrey Cilley, MD
Medical Director, Swedish Hospital Cancer Center, President of Medical Staff, Swedish Hospital
Expertise: Benign and Malignant Hematology; Medical Subspecialty: Breast Oncology
Location: SW



Sebouh Gueyikian, MD
Section Head, Interventional Radiology
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Julian Bailes, MD
Chair, Department of Neurosurgery Co-Director, NorthShore Neurological Institute
Expertise: Brain Tumors; Brain Disorders; Aneurysms; Spinal Disorders; Epilepsy Surgery; General Neurosurgery
Locations: EV, HPH




Peter Colegrove, MD
Expertise: Sexual Dysfunction; Incontinence; Prostate Health; Kidney Stones; Vasectomy
Locations: EV, GB



Harold Hamann, MD
Expertise: General Urology; Endourology; Kidney Stones; Benign Prostate Hyperplasia; Prostate Cancer; Kidney Cancer
Location: SH



William Bloomer, MD
Chair, Department of Radiation Oncology
Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer
Locations: EH, HPH



Allison DePersia, MD
Expertise: Hematology Oncology; High Risk Breast Cancer
Location: EV



Britt Hanson, DO
Expertise: Melanoma, Benign and Malignant Hematology
Locations: GR, HPK



Bruce Brockstein, MD
Division Head, Hematology/Oncology, Medical Director, Kellogg Cancer Center; Kellogg-Scanlon Chair of Oncology
Expertise: Head and Neck Cancers; Melanoma; Sarcoma
Locations: EVK, HPK




Nisha Desai, MD
Expertise: Adult and Pediatric Dermatology; General Dermatology; Laser and Surgical Treatment of Birthmarks; Hemangioma
Locations: MP, SK



Herbert Mason Hedberg, MD
Expertise: Gastrointestinal, Esophageal and General Surgery
Locations: EV, HP

continued >



Brian Helfand, MD, PhD
Division Head, Urology
 Expertise: Prostate Cancer; Benign Prostatic Hyperplasia; Laparoscopic Surgery; Robotic Assisted Surgery; Laser Surgery
 Location: GB



Amanda Silver Karcioglu, MD
 Expertise: Head and Neck Surgery; Thyroid/Parathyroid Surgery
 Locations: EVK, LB, SK



Daniel Laich, MD
 Expertise: Spine Tumors
 Location: SW



Anshu Hemrajani, MD
 Expertise: Breast Cancer
 Locations: GBK, HPK



Deborah Katz, MD
 Expertise: Benign and Malignant Hematology
 Location: GBK, HPK



Elyse Lambiase, MD
 Expertise: Benign and Malignant Hematology; Medical Oncology
 Location: SW



Thomas Hensing, MD, MS
Co-Director of the Thoracic Oncology Program, Associate Head Quality Officer for Ambulatory Care
 Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers
 Locations: EVK, GBK




James Kearns, MD
 Expertise: Prostate Cancer; Benign Prostatic Hyperplasia; Laparoscopic Surgery; Robotic Assisted Surgery; Laser Surgery
 Locations: EV, GB



Teresa Murray Law, MD
 Expertise: Breast Cancer
 Locations: EVK, HPK



Melissa Hogg, MD, MS
Division Head, Gastrointestinal and General Surgery
Director, Liver and Pancreas Surgery
 Expertise: Gastrointestinal Surgical Oncology; Pancreatic Cancer; Primary and Metabolic Liver Tumors; Neuroendocrine Tumors; Cancers of the Stomach and Duodenum; Benign Hepatobiliary
 Locations: EVK, GBH, SW



Janardan Khandekar, MD
Director, Center for Molecular Medicine
 Expertise: Endocrine; Breast Cancer
 Location: EV



Ross Levy, MD
 Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery; Cosmetic Surgery
 Location: SK



Peter Hulick, MD, MMSc
Division Head, Medical Genetics
Director, Center for Personalized Medicine
 Expertise: Cardiovascular and Cancer Genetics; Pharmacogenomics; Personalized Medicine
 Location: EV, HPK




Carolyn Kirschner, MD
 Expertise: Gynecologic Oncology; Cancer Survivorship
 Locations: EVK, GBK



Melissa Hachen Lippitt, MD, MPH
 Expertise: Gynecologic Oncology
 Locations: EVK, GBK



Javed Imam, MD
 Expertise: Benign and Malignant Hematology, Medical Oncology
 Location: SW




Katherine Kopkash, MD
Director of Oncoplastic Breast Surgery
 Expertise: Breast Cancer; Oncoplastic Breast Surgery; Breast Health; Breast Disease and Surgery
 Locations: EV, GB



Luzheng Liu, MD
 Expertise: General Dermatology; Skin Cancers
 Location: LB



Mary Tilley Jenkins Vogel, MD
 Expertise: Gynecologic Oncology
 Locations: EVK, GBK, SW




Seth Krantz, MD
Division Head, Thoracic Surgery
Chairman, NorthShore Cancer Committee
 Expertise: Lung Cancer; Esophageal Cancer; Benign Esophageal Disease; Diseases of the Chest Wall and Pleura; Minimally Invasive Thoracic Surgery; Bronchoscopy; Endobronchial Ultrasound; Esophagoscopy
 Locations: EVK, HPK, NCH



Robert Marsh, MD
Section Head, GI Oncology
 Expertise: GI Oncology
 Locations: EVK, GBK



Andrew Johnson, MD
 Expertise: Neurological Surgery, Neurosurgery, Cervical Spine Surgery, Minimally Invasive Spine Surgery; Complex Spine Surgery, Brain and Spine Tumors
 Location: SW



Monika Krezalek, MD
Director, Rectal Cancer Program
Cancer Liaison Physician, NorthShore Cancer Committee
 Expertise: Minimally Invasive Colon and Rectal Surgery; Inflammatory Bowel Disease; Anorectal Surgery; Colonoscopy; Pelvic Floor Disorders
 Locations: EV, HPH, VH



Gregg Menaker, MD
 Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery; Cosmetic Surgery
 Location: SK



Lynne Kaminer, MD
Section Head, Hematology
 Expertise: Benign and Malignant Hematology
 Locations: EVK, GBK



Craig Labbate, MD
 Expertise: Bladder Cancer, Kidney Cancer, Prostate Cancer, Robotic Surgery
 Locations: EV, GBH, HPH



Douglas Merkel, MD
 Expertise: Breast Cancer
 Locations: EVK, GBK, HPK



Cecylia K. Mizera, MD
 Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
 Location: SW



Catherine Pesce, MD
Division Head, Surgical Oncology
 Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
 Locations: EV, HP



Jason Robin, MD
 Expertise: Cardio-Oncology
 Location: GB



Tricia Moo-Young, MD
 Expertise: Minimally Invasive Approaches to Endocrine Disorders; Thyroid and Parathyroid Surgery; Adrenal Disorders; Cancer and Disease Management
 Locations: HPH, SK




Nicklas Pfanzerler, MD
 Expertise: Genitourinary Cancer, Prostate Cancer, Melanoma
 Locations: EVK, GBK, HPK



Gustavo Rodriguez, MD
Division Head, Gynecologic Oncology
 Expertise: Gynecologic Oncology
 Location: EVK



Elena Moore, MD
 Expertise: Gynecologic Oncology
 Locations: EVK, HPK




Elizabeth Poli, MD
 Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
 Locations: GB, HPB, VH



Carol Rosenberg, MD
Director, Preventive Health Initiatives; Director, Myra Rubenstein Weis Living in the Future (LIFE) Cancer Survivorship Program
 Expertise: Cancer Survivorship
 Location: HPH



Joseph Muldoon, MD
 Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease; General Surgery
 Locations: EV, GB



Ariel Polish, MD
 Expertise: GI Oncology; Benign and Malignant Hematology; Lung Cancer
 Locations: EVK, GBK, GR



Poornima Saha, MD
 Expertise: Breast Cancer
 Locations: EVK, GBK



Ranjeev Nanda, MD
 Expertise: Stereotactic Radiosurgery; Brain Tumors; Head and Neck Cancers; Prostate
 Locations: EH, GBH



Amit Pursnani, MD
 Expertise: Cardio-Oncology
 Location: SK



Akhil Seth, MD
 Expertise: Breast Reconstruction; Aesthetic Breast and Body Surgery; Oncologic Reconstruction
 Location: NMB



Kristian Novakovic, MD
 Expertise: Bladder Cancer; Kidney Cancer; Prostate Cancer; Minimally Invasive Techniques: Laparoscopy and da Vinci Robot
 Locations: EV, GB



Vathsala Raghavan, MD
 Expertise: Thyroid Cancer; Breast Cancer; Gynecologic Oncology; Head and Neck Cancers
 Locations: EH, GBH, HPH



Arif Shaikh, MD
 Expertise: Stereotactic Radiosurgery; Head and Neck Cancers; Lung Cancer; Gynecologic and Breast Tumors, Prostate
 Locations: EH, GBH



Sangtae Park, MD, MPH
 Expertise: Prostate Cancer; Urologic Oncology
 Locations: EV, GB



Joseph Raviv, MD
Division Head, Otolaryngology
 Expertise: Nasal and Sinus Surgery; Endoscopic Skull Base Surgery
 Locations: NMB, SK, SW



Daniel Shevrin, MD
Medical Director, Glenbrook Kellogg Cancer Center
 Expertise: Prostate Cancer; Genitourinary Cancer
 Locations: EVK, GBK



Rupa Patil, MD
 Expertise: Cardio-Oncology
 Locations: EV, GB



Sidney Regalado, MD
 Expertise: Interventional Radiology
 Locations: EH, GB, HP, SK



Hayley Silver, MD
 Expertise: Benign Prostate Hyperplasia; Kidney Stones; Male Bladder Symptoms; Vasectomy
 Locations: EV, LV, SW



Anita Vasan Pattani, MD
 Expertise: Internal Medicine; Hospice and Palliative Medicine
 Locations: EV, GB, HP, SK



Mary Rhodes, MD
 Expertise: Internal Medicine; Hospice and Palliative Medicine
 Locations: EV, GB, HP, SK




Mark Sisco, MD
Division Head, Plastic Surgery
 Expertise: Aesthetic Surgery; Breast and Body Surgery; Breast Reconstruction; Microsurgery
 Location: NMB

continued >




Thomas (T.J.) Smith, MD
 Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
 Locations: SK, SW



Elaine Lee Wade, MD
 Expertise: Breast Cancer
 Location: GBK



Alan Smookler, MD
Division Head, Palliative Care
 Expertise: Internal Medicine; Geriatrics; Hospice and Palliative Medicine
 Locations: EV, GB, HP, NCH, SK



Jason Waldinger, MD
Division Head, Dermatology
 Expertise: General Dermatology; Skin Cancer
 Location: LB



James Spitz, MD
 Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancers; Advanced Lower Endoscopy
 Locations: GB, HPH, VH



Amy Wang, MD
 Expertise: Benign and Malignant Hematology
 Location: EVK



Katherine Wailen Su, MD
 Expertise: Lung Cancer; Esophageal Cancer; Benign Esophageal Disease; Paraesophageal Hernias; Mediastinal Masses; Diseases of Chest Wall and Pleura; Minimally Invasive Surgery; Advanced Endoscopy/Bronchoscopy
 Locations: EVK, NCH, SW



K.T. Weber, MD
 Expertise: Minimally Invasive Colon and Rectal Surgery
 Locations: GB, SK, SW



Auddie Sweis, MD
 Expertise: Nasal and Sinus Surgery; Endoscopic Skull Base Surgery
 Locations: LB, SKM, SW



Lauren Wiebe, MD
 Expertise: Palliative Medicine; GI Oncology
 Locations: EV, EVK, GB, GBK, HP, NCH, SK



Mark Talamonti, MD
Department Chair, Surgery
 Expertise: Gastrointestinal Surgical Oncology; Pancreatic Cancer; Benign and Malignant Liver Tumors; Neuroendocrine Tumors; Foregut Cancers of the Esophagus; Sarcoma
 Location: EVK



Ricky Wong, MD
 Expertise: Deep Brain and Vagal Nerve Stimulators; Brain and Skull Base Tumors; Pituitary Tumors; Cerebral Aneurysms; Arteriovenous Malformation (AVM); Trigeminal Neuralgia
 Locations: EV, GB, LV



Leslie Mendoza Temple, MD
Medical Director, Integrative Medicine
 Expertise: Integrative Medicine
 Location: GP



Katharine Yao, MD
Vice Chair, Research and Development
Department of Surgery
 Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
 Locations: EV, GB



Christopher Trevino, MD
 Expertise: Neuro-Oncology
 Locations: EV, EVK, GBK



Andrew Zelby, MD
 Expertise: Pituitary Tumors
 Location: LV



Michael Ujiki, MD
Vice Chair for Clinical Affairs, Gastrointestinal and General Surgery
 Expertise: Minimally Invasive Surgery; Esophageal Surgery; Gastric Surgery; Bariatric Surgery; Flexible Endoscopy; Gallbladder Surgery
 Locations: EV, GB

Breast Cancer Conferences

NorthShore Evanston Hospital
 Kellogg Room G868, Mondays, 7:30 a.m.
 NorthShore Glenbrook and Highland Park Hospitals Videocast

Colorectal Cancer Conferences

NorthShore Evanston Hospital
 Kellogg Room G868
 2nd and 4th Fridays, 7 a.m.
 NorthShore Glenbrook and Highland Park Hospitals Videocast

Genitourinary Cancer Conferences

NorthShore Evanston Hospital
 Kellogg Room G868
 1st and 3rd Fridays, 7 a.m.
 NorthShore Glenbrook Hospital Videocast

Gynecology Cancer Conferences

NorthShore Evanston Hospital
 Kellogg Room G868, Thursdays, 7 a.m.
 NorthShore Glenbrook and Highland Park Hospitals Videocast

Head and Neck Cancer Conferences

NorthShore Evanston Hospital
 Kellogg Room G868
 1st and 3rd Thursdays, 8 a.m.

Hematology/Pathology Conferences

NorthShore Evanston Hospital
 Kellogg Room G868, Tuesdays, 8 a.m.
 NorthShore Glenbrook and Highland Park Hospitals Videocast

Hepatic Biliary Pancreatic Cancer Conferences

NorthShore Evanston Hospital
 Kellogg Room G868, Tuesdays, 6:30 a.m.
 NorthShore Glenbrook and Highland Park Hospitals Videocast

Molecular Oncology Conferences

NorthShore Evanston Hospital
 Kellogg Room 4818, 1st Friday, 7 a.m.

Neuro-Oncology Cancer Conferences

NorthShore Evanston Hospital
 Kellogg Room G868
 2nd and 4th Wednesdays, 7:30 a.m.
 NorthShore Glenbrook and Highland Park Hospitals Videocast

Sarcoma/Melanoma Conferences

NorthShore Evanston Hospital
 Kellogg Room G868
 1st and 3rd Wednesdays, 8 a.m.
 NorthShore Glenbrook and Highland Park Hospitals Videocast

Thoracic Cancer Conferences

NorthShore Evanston Hospital
 Kellogg Room G868, Tuesdays, noon
 NorthShore Glenbrook and Highland Park Hospitals Videocast

Locations

Evanston Breast Center (EVB)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Hospital (EH)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Kellogg Cancer Center (EVK)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Specialty Suites (EV)

1000 Central Street, Evanston, IL 60201

Glenbrook Breast Center (GBB)

2050 Pfingsten Road, Suite 130

Glenview, IL 60026

Glenbrook Hospital (GBH)

2100 Pfingsten Road, Glenview, IL 60026

Glenbrook John and Carol Walter Ambulatory Care Center (GB)

2180 Pfingsten Road, Glenview, IL 60026

Glenbrook Kellogg Cancer Center (GBK)

2180 Pfingsten Road, Suite 1000

Glenview, IL 60026

Glenbrook Medical Building (GBM)

2050 Pfingsten Road, Suite 128

Glenview, IL 60026

Glenview Park Center (GP)

2400 Chestnut Avenue, Glenview, IL 60026

Gurnee Ambulatory Care Center (GR)

7900 Rollins Road, Gurnee, IL 60031

Highland Park Ambulatory Care Center (HPS)

757 Park Avenue West

Highland Park, IL 60035

Highland Park Breast Center (HPB)

777 Park Avenue West, Suite B400

Highland Park, IL 60035

Highland Park Hospital (HPH)

777 Park Avenue West, Room 1260

Highland Park, IL 60035

Highland Park Kellogg Cancer Center (HPK)—

Ellen Marks Ambulatory Care Center

757 Park Avenue West, Suite 1810

Highland Park, IL 60035

Highland Park Medical Building (HP)

767 Park Avenue West, Suite B100

Highland Park, IL 60035

Lake Bluff Medical Building (LB)

71 Waukegan Road, Suite 700

Lake Bluff, IL 60044


Lakeview Medical Group (LV)

3122 N. Ashland Avenue

Chicago, IL 60657

Mount Prospect Medical Building (MP)

1329 Wolf Road, Mount Prospect, IL 60056



Northbrook Medical Building (NMB)

501 Skokie Boulevard

Northbrook, IL 60062

NorthShore Medical Group (SKM)—Skokie

9933 Woods Drive, Suite 200

Skokie, IL 60077

Northwest Community Healthcare (NCH)

880 West Central Road, Suite 4100

Arlington Heights, IL 60005

Skokie Ambulatory Care Center (SK)

9650 Gross Point Road, Suite 3000

Skokie, IL 60076

Skokie Medical Group (SKM)

9669 Kenton Avenue, Suite 206

Skokie, IL 60076

Swedish Hospital (SW)

5140 N. California Avenue

Chicago, IL 60625

Vernon Hills Specialty Suites (VH)

225 North Milwaukee Avenue

Vernon Hills, IL 60061

Wilmette Medical Office (WM)

1515 Sheridan Road, Suite 31A

Wilmette, IL 60091

Evanston Hospital

2650 Ridge Avenue, Evanston, Illinois 60201
(847) 570-2000

Glenbrook Hospital

2100 Pfingsten Road, Glenview, Illinois 60026
(847) 657-5800

Highland Park Hospital

777 Park Avenue West, Highland Park, Illinois 60035
(847) 432-8000

Northwest Community Healthcare/Hospital

800 West Central Road, Arlington Heights, IL 60005
(847) 618-1000

Skokie Hospital

9600 Gross Point Road, Skokie, Illinois 60076
(847) 677-9600

Swedish Hospital

5140 N. California Avenue, Chicago, IL 60625
(773) 878-8200

Medical Group

1301 Central Street, Evanston, Illinois 60201
(847) 570-5235

Foundation

1001 University Place, Suite 248
Evanston, Illinois 60201
(224) 364-7600


Research Institute

1001 University Place, Evanston, Illinois 60201
(224) 364-7100



1301 Central Street
Evanston, Illinois 60201

northshore.org



Scan for more information

2023 Cancer Committee

Chairman

Seth Krantz, MD

Division Head, Thoracic Surgery
Kellogg Cancer Center

Cancer Liaison Physician

Monika Krezalek, MD

Director, Rectal Cancer Program

Physician Membership*

Bruce Brockstein, MD

Medical Director,
Kellogg Cancer Center
Head, Division of Hematology/Oncology
Kellogg-Scanlon Chair of Oncology

Carolina Soto Chervin, MD**David Grinblatt, MD**

Medical Director, Cell Therapy

Elena Moore, MD**Kristian Novakovic, MD****Ajit Paintal, MD****Catherine Pesce, MD**

Division Head, Surgical Oncology

Nicklas Pfanzer, MD

Clinical Research Coordinator
Quality Improvement Coordinator

Vathsala Raghavan, MD**Carol Rosenberg, MD**

Director, Myra Rubenstein Weis
Living in the Future (LIFE)
Cancer Survivorship Program
Survivorship Program Coordinator

Poornima Saha, MD**Georgia Spear, MD**

Section Head, Breast Imaging

Lauren Wiebe, MD

* All academic affiliations are with the University of Chicago Pritzker School of Medicine

Ancillary Membership

Kim Cholewa, BSN

Clinical Nurse Manager,
5S Searle

Jamie Feld, MS/MPH, RN

Oncology Accreditation and
Quality Coordinator

Nancy Flowers, LCSW, MSW

Psychosocial Services
Coordinator

Kiley Telles Gregory, RDN, LDN

Oncology Nutrition

Rachel Hollander

Public Relations

Sharon Huginnie

Senior Applications Analyst I
Epic IP/HOV Team
Health Information Technology

Elizabeth Kacel, PhD

Clinical Psychologist

Kaitlyn Keen

American Cancer Society

Aviva Matanky, RN, OCN

Clinical Nurse Manager,
Evanston Kellogg Cancer Center

Rachel Mees, MBA

Cancer Program Administrator,
Medical Group
Kellogg Cancer Center

Sabina Omercajic, MS, CCRP

Outreach Coordinator

Anisha Patel, APN

Clinical Coordinator,
MRW Living in the Future
(LIFE) Cancer Survivorship
Program

Dipale Patel, PharmD

Senior Director, Oncology
Pharmacy

Kyle Pietro

Clinical Coordinator,
Oncology Support Services,
Kellogg Cancer Centers

Shayna Purcell, MS, CGC

Medical Genetics

Amanda Schell, MS, OTR/L

Rehabilitation Services

Frank Soucek, MSN, MBA, RN, NE-BC

Clinical Director, Kellogg
Cancer Center

Debra Ziegler, MLIS, CTR

Cancer Registry Quality
Coordinator
Cancer Conference
Coordinator